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Purpose: 
The serotonergic system is related to various dysfunctions in the central nervous 
system, such as depression, social anxiety disorder, and epilepsy. Thus, the 
development of a radioactive probe for imaging serotonin synthesis is important for 
the diagnosis of such diseases. α-[11C]Methyltryptophan ([11C]AMT) is available for 
the imaging of serotonin synthesis. However, the brain uptake of [11C]AMT reflects 
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both serotonin and kynurenine metabolism. In addition, since tryptophan is rapidly 
cleared from the brain, α-methylation would be needed to prolong the retention time 
in the brain and reduce the metabolism by monoamine oxidase (MAO). In the present 
study, we designed and synthesized 18F- labeled [18F]trifluoromethyl-L-tryptophan 
([18F]CF3-L-Trp) and [18F]trifluoromethyl-L-α-methyl tryptophan ([18F]CF3-L-AMT) 
which might be metabolized to serotonin only. To evaluate the feasibility of labeled 
tryptophan derivatives for imaging the serotonergic system, the distribution and 
metabolism were investigated in rat brain. 
 
Methods:  
 Precursor of [18F]CF3-L-Trp or [18F]CF3-L-AMT was prepared by regio-selective 
iodination using palladium or mercury catalyst, respectively. [18F]Trifluromethyl 
group was introduced by copper-catalyzed coupling using methyl 
chlorodifluoroacetate and tetramethylenediamine at 150C for 15 min. Protecting 
groups were removed by 1 N HCl at 100C for 10 min. The reaction mixture was 
purified by HPLC and radiochemical and enantiomeric purities were measured by 
HPLC. Biodistribution was performed in normal BALB/c mice at 10, 60 and 120 min 
post injection. For the autoradiography, [18F]CF3-L-Trp and [18F]CF3-L-AMT were 
injected into rats by tail vein injections without anesthesia. PET studies were 
performed in SD rat by intravenous administration of [18F]CF3-L-Trp. Metabolite 
study was performed in BALB/c mice using non-radioactive CF3-L-Trp and brain, 
blood, and urine samples were analyzed by HPLC and LC/MS. To evaluate brain 
- 4 - 
 
distribution of [18F]CF3-L-AMT in serotonin metabolism enhanced SD rat, lithium 
chloride was administered to rats 2 times per day for 5 days (85 mg/kg, i.p.).  
 
Results:  
 Protected L-Trp and its bromo and iodo derivatives were tested for 
[18F]trifluoromethylation and iodo derivative showed the highest labeling efficiency. 
Radiochemical yield was 6±1.5% based on the isolated product and radiochemical 
purity was over 99%. The molar activity of [18F]CF3-L-Trp was 0.44–0.76 GBq/μmol 
and [18F]CF3-L-AMT was 0.94–1.44 GBq/μmol which are enough for in vivo 
application. Enantiomeric purity was measured by chiral HPLC and no racemic form 
was found. In the biodistribution, at 10 min, the brain uptakes of [18F]CF3-L-AMT 
and [18F]CF3-L-Trp were 2.27 ± 0.14%ID/g and 2.06 ± 0.22%ID/g, respectively and 
the brain uptake of [18F]CF3-L-AMT (0.73 ± 0.08%ID/g) at 60 min was significantly 
higher than that of [18F]CF3-L-Trp (0.43 ± 0.08%ID/g). This result indicated that α-
methylation increased the retention in the brain by reducing metabolism by MAO. 
The bone uptake of [18F]CF3-L-AMT at 60 min (4.50 ± 0.47%ID/g) was significantly 
lower than that of [18F]CF3-L-Trp (9.34 ± 0.62%ID/g), suggesting the lower in vivo 
defluorination of [18F]CF3-L-AMT. Both of the tracers showed high uptakes in the 
kidney. In PET and autoradiography measurements, the uptake of raphe nucleus 
(dorsal and medial) was comparatively very low. Instead, pineal gland, thalamus, 
hypothalamus and midbrain showed particularly high uptake. [18F]CF3-L-Trp 
penetrated the blood-brain barrier via the L-type amino acid transporter, while 
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[18F]CF3-D-Trp did not. In the metabolism study, CF3-serotonin peak was found in 
brain and blood at 60 min, and the mass value of the CF3-serotonin peak was 
confirmed by LC-MS. The distribution pattern of [18F]CF3-L-AMT in Li-treated SD 
rat brains was similar to that detected in normal SD rat brains. However, the brain 
uptake rate of [18F]CF3-L-AMT in Li-treated SD rats was faster than normal SD rats 
and the brain uptake in Li-treated SD rats lasted longer than that in normal SD rats. 
  
Conclusion:  
[18F]CF3-L-Trp could be successfully synthesized by 
[18F]trifluoromethylation, but fast washout from the brain and high in vivo 
defluorination showed that [18F]CF3-L-Trp was not suitable for imaging the 
serotonergic system. α-Methylation of tryptophan increased the retention in the 
brain by reducing metabolism and might decrease the in vivo defluorination. 
However, it is not clear that the PET imaging of [18F]CF3-L-Trp reflect serotonin 
metabolism due to the low uptake in raphe nucleus. A large unmetabolized form in 
the brain also makes it difficult to obtain the absolute serotonin synthesis rate. 
Nevertheless, experimental data suggest that the distribution patterns of [18F]CF3-L-
AMT in normal and Li-treated SD rats were related with serotonergic activity and 
metabolism. Therefore, [18F]CF3-L-AMT could be used as an feasible imaging 
agent representing serotonergic system. 
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1 INTRODUCTION 
   Serotonin (5-hydroxytryptamine (5-HT)) is a major neurotransmitter in the 
serotonergic system, and contains an indole ring in its structure. The serotonergic 
system of the central nervous system (CNS) originates from the raphe nuclei and 
projects throughout the whole brain. This widespread system controls a variety of 
psychological functions. Studies have investigated whether altered levels of serotonin 
synthesis could be used as diagnostic tools for depression,1 social anxiety disorder 
(SAD),2 epilepsy,3 attention deficit hyperactivity disorder (ADHD),4 Alzheimer’s 
disease (AD),5 or brain cancers6-8 and found that the increased or decreased synthesis 
of serotonin is associated with those diseases. 
Serotonin is synthesized from the essential amino acid L-tryptophan (Trp) by 
serotonin neurons, mainly in synaptic endings. As the cell bodies of serotonin neurons 
are located in the raphe nuclei and protect into the almost every region of the brain9. 
The biosynthetic precursor of serotonin is Trp, which is metabolized to serotonin by 
a two-step enzymatic process (Figure 1): 5-hydroxylation of L-Trp and 
decarboxylation of 5-hydroxytryptophan (5-HTP). The first 5-hydroxylation step is 
the rate-limiting step,10 and the enzyme for this process is located only in the 
serotonergic neurons.11 The second decarboxylation step by aromatic amino acid 
decarboxylase (AAAD) is fast and less specific.12  
Alternatively, L-Trp can also be metabolized by Trp dioxygenase at the 2- and 3-
positions of the indole ring and enter the kynurenine pathway (Figure 1), which is a 
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biosynthetic pathway for nicotinamide adenine dinucleotide (NAD) and is highly 
activated in inflammatory conditions.13 
Tryptophan derivatives labeled with positron emitters have been developed for 
the imaging of serotonin synthesis in the brain. Among them, α-[11C]methyl- L-
tryptophan ([11C]AMT) is the most widely studied PET agent.14-16 Autoradiograms in 
rats demonstrated that [11C]AMT is highly accumulated in dorsal raphe nuclei in 
which serotonergic cell bodies are located14. The metabolism of AMT into α-methyl-
serotonin was also confirmed by HPLC17. [3H]AMT was located to serotonergic 
neurons in raphe nucleus and confirmed by tryptophan hydroxylase 
immunocytochemistry simultaneously at the electron microscopic level18. Despite of 
these studies, there are still disadvantages of the presence of a large unmetabolized 
pool and entering the kynurenine pathway as well (Figure 2).7,19 Especially, 
[11C]AMT can be metabolized via both serotonin and kynurenine pathway by the 
action of serotonin hydroxylase and indole 2,3-dioxygenase (IDO), respectively. 
Serotonin pathway is major in normal condition, and kynurenine pathway is major in 
certain pathologic condition, such as ischemic brain injury or immune activation by 
the increased activity of IDO20,21. So the uptake of [11C]AMT may not accurately 
represent serotonin synthesis especially in an inflammation condition. Furthermore, 
short half-life of 11C (20 min) restricts its use to facilities equipped with a cyclotron 
and automatic synthesis module. 5-Hydroxy-[β-11C]- L-tryptophan ([11C]HTP) was 
also used for measuring of serotonin synthesis rate. Although it was metabolized in 
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the exact same way as endogenous 5-HTP, it was metabolized not only to [11C]5-HT 
but also to [11C]HIAA and rapidly excreted from the brain in rodent22. 
Recently, 4-, 5-, 6-, and 7-[18F]fluorotryptophan derivatives have been tested for 
imaging serotonin synthesis in vivo.23 Among them, 4-, 5-, and 6-
[18F]fluorotryptophan are metabolized by IDO or tryptophan 2,3-dioxygenase (TDO) 
and show rapid defluorination and high bone uptake.24,25 Only 7-
[18F]fluorotryptophan exhibited slow defluorination and high uptake in the 
melatonin-producing pineal gland and serotonergic areas of the rat brain.23 However, 
the possibility of these compounds entering the kynurenine pathway still remains, 
because the 2-position of their indole rings is not protected from dioxygenation. 
To develop a novel 18F-labeled Trp derivative that reflects only the serotonin 
pathway and not the kynurenine pathway, we first attempted to synthesize 2-
[18F]fluorotryptophan, which might be resistant to indole dioxygenase. Since indole 
dioxygenase oxidizes the 2- and 3-positions of the indole ring, we expected that 
substituting a fluorine atom at the 2-position might protect it from oxidation due to 
its electron-withdrawing effect. Even if [18F]fluorine was able to be labeled at 5-
position, there was still a possibility that 5-[18F]fluorotryptophan could be 
metabolized to kynurenine analog. Moreover, since tryptophan hydroxylase which 
exists in serotonin neuron specifically acts on position-5, [18F]fluorine prevent the 
enzymatic process of 5-hydroxylation.    
2-Halotryptophan derivatives can be synthesized by electrophilic substitution, 
and we supposed that 2-fluorotryptophan could also be synthesized.26,27 However, its 
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synthesis by the introduction of [18F]fluoride at the 2-position of the indole ring via 
nucleophilic substitution was not successful due to the electron-rich ene-amine 
structure (Figure 3A). We succeeded in synthesizing a 2-fluorotryptophan derivative 
protected with Boc and a methyl group at the amino and carboxyl groups, respectively, 
using a tributyltin-functionalized precursor purged with 0.1% F2 gas in Ne by 
electrophilic substitution. However, when we attempted to label tributyltin-
functionalized precursor with 18F, the indole ring moiety was easily degraded in acid, 
and we failed to obtain the 2-[18F]fluorotryptophan derivative (Figure 3B). 2-
Chlorotryptophan has been reported to be less stable than 2-bromotryptophan to acid 
treatment, which is an essential step in 18F-labeling.28 Thus, 2-[18F]fluorotryptophan 
was supposed to be even less stable and more susceptible to acid than 2-
chlorotryptophan, and thus could not be obtained. Another attempt to prepare 2-
trimethylammoniumtryptophan protected with trifluoroacetyl residue as a precursor 
for 2-[18F]fluorotryptophan was unsuccessful, as the intermediate 2-aminotryptophan 
was unstable and rapidly oxidized in air (Figure 3C).29 
We then tried to synthesize [18F]trifluoromethyltryptophan ([18F]CF3- L-Trp), 
which might be stable in acidic condition for hydrolysis. Previous reports indicated 
that [18F]CF3 could be introduced into electron-rich arenes or heteroarenes 
functionalized with halogen atoms via a copper(I)-mediated cross-coupling reaction 
(Figure 4).30,31 We treated the 2-chloro, 2-bromo, 2-iodo, and 2-trifluorotryptophan 
derivatives with a TFA solution, and found that only the 2-trifluoromethyl tryptophan 
derivative was stable in acid. The 2-chloro and 2-bromotryptophan derivatives 
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rapidly decomposed, and the 2-iodotryptophan derivative was rapidly deiodinated 
into L-Trp. 
However, there was still challenge for measuring in vivo serotonin synthesis using 
radiolabeled tryptophan derivative. As serotonin is rapidly metabolized into 5-
hydroxyindoleacetic acid (HIAA) by monoamine oxidase (MAO) and released from 
the brain, the brain radioactivity cannot reflect the ongoing synthesis of serotonin. 
Although pharmacological treatment was tried to inhibit MAO or AADC and to 
accumulate endogenous serotonin, the effect of the drugs distorted the data making 
interpretation of data and quantitative conclusions more difficult. To enhance the 
metabolic characteristic, α-methyl group was introduced into tryptophan. α-
Substituted tryptophan derivatives may be resistant to monoamine oxidase (MAO) 
and accumulated in the tissue (probably in the neurons)32 because α-substitution 
dramatically increase the resistance to hydrolysis33,34. Hence, α-substituted 
tryptophan derivatives don’t require the intervention of a serotonin metabolism 
inhibitor like NSD-1095 to increase nerve cell retention35.  
In the present study, we tried to develop [18F]CF3-L-Trp for serotonin 
metabolism PET imaging. Protected L-Trp and its bromo and iodo derivatives at the 
2-position of Trp were tested for [18F]trifluoro methylation as precursors. The serum 
stability and protein binding of [18F]CF3- L-Trp were examined in vitro. To evaluate 
the feasibility of [18F]CF3-L-Trp for imaging serotonin metabolism, a biodistribution, 
autoradiography, PET, and metabolism studies were performed in rodents. 
[18F]Trifluoromethyl-L-α-methyltryptophan ([18F]CF3-L-AMT) was also developed 
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to prolong the brain retention and reduce the metabolism. Even if the α-methyl 
modification on tryptophan may affect the transport into the brain through the blood-
brain barrier (BBB) or serotonin neurons, it can exhibit better metabolic properties 













FIGURE 1. Metabolism of Trp. Trp is metabolized to serotonin by 5-hydroxylation 
and subsequent decarboxylation (left). However, it also is metabolized to kynurenine 
after 2,3-dioxygenation by IDO or TDO (right). A Trp derivative having substituent 
at the 5-position may proceed to the kynurenine pathway, while one substituted at the 










FIGURE 2. Limitation of AMT for imaging of serotonin metabolism. IDO, indole 
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FIGURE 3. Trials for the labeling the 2-position of tryptophan with [18F]fluorine. 
[18F]Fluorination was attempted by (A) nucleophilic substitution using 2-
halotryptophan, (B) electrophilic substitution using 2-tributyltintryptophan, and (C) 
introduction of trimethylammonium after the synthesis of 2-aminotryptophan, which 
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FIGURE 4. Proposed mechanism of [18F]trifluoromethylation. [18F]CF3 can be 
introduced into tryptophan via copper(I)-mediated cross coupled 
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2 MATERIALS AND METHODS 
2.1 General  
L-Trp methyl ester hydrochloride was purchased from TCI (Tokyo, Japan) and 
used without further purification. 2-Bromo-L-Trp methyl ester26 and 2-iodo-L-Trp 
methyl ester27 were prepared according to previously published procedures. AMT 
racemic mixture was purchased from Chemi-Impex International (IL, USA). The 
other reagents and solvents were purchased from Acros organics (Thermo Fisher 
Scientific, MA, U.S.A.), TCI (Tokyo, Japan) or Sigma-Aldrich (MO, U.S.A.) and 
were used as received. All non-aqueous reactions were performed under an inert 
atmosphere of dry argon or N2 gas. Reactions were monitored by thin layer 
chromatography (TLC) using Merck Kieselgel 60 F254 plates or high performance 
liquid chromatography (HPLC) (Gilson Inc., WI, U.S.A.). The spots were detected 
under UV light (254 nm) and developed using ninhydrin or anisaldehyde. Flash 
column chromatography was carried out on silica gel 60 (230-400 mesh), and all 
chromatographic solvents were of HPLC grade. 1H and 13C nuclear magnetic 
resonance (NMR) spectra were obtained using a 300-MHz Al-300 FTNMR 
spectrometer (JEOL Ltd., Tokyo, Japan) and 19F NMR spectra were obtained using 
600 MHz High Resolution NMR spectrometer (AVANCE 600, Bruker, Germany). 
Chemical shifts (δ) were recorded in parts per million (ppm) relative to 
tetramethylsilane (TMS) using the deuterated solvent as an internal reference, and 
coupling constants (J) were reported in unit of hertz (Hz). The following 
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abbreviations are used to describe multiplicities: s (singlet), d (doublet), t (triplet), q 
(quartet), and m (multiplet). Mass spectra (m/z) were recorded on a LTQ velos 
spectrometer (Thermo Fisher Scientific, MA, U.S.A.) or a Waters 3100 liquid 
chromatography-mass spectroscopy (LC-MS) (Waters Corporation, MA, U.S.A.) 
using positive electrospray ionization (ESI+). High resolution mass spectra (HRMS, 
m/z) were acquired on a LTQ-Orbitrap Velos ion trap spectrometer (Thermo Scientific, 
France) 
[18F]Fluoride was produced via the 18O(p,n)18F reaction with 18O-enriched (98%) 
water using a 16.5-MeV proton beam generated by a PETtrace 10 cyclotron (GE 
Healthcare, Uppsala, Sweden). Automated radiosyntheses for animal studies were 
performed in a TRACERLab Fx-FN module (GE Medical Systems, Germany) 
equipped with preparative HPLC with a Geiger-Mueller detector. The radiochemical 
purity, specific activity, and chiral purity were measured using analytical HPLC 
connected to a Gabi Star flow-through gamma radioactivity detector (Raytest GmbH, 
Germany). The dose calibrator (Atomlab 100; Biodex Medical Systems, Inc., New 
York, NY, U.S.A.) was used for measuring the level of radioactivity. In vivo 
metabolites of unlabeled CF3-L-Trp were analyzed using HPLC and mass 
spectrometry (MS). All animal studies were carried out with the approval of 
Institutional Animal Care and Use Committee of Clinical Research Institute, Seoul 
National University Hospital. This facility was accredited by the Association for the 
Assessment and Accreditation of Laboratory Animal Care International. In addition, 
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National Research Council guidelines for the care and use of laboratory animals 
(revised in 1996) were observed throughout. 
 
2.2 [18F]Trifluoromethyl- L-tryptophan ([18F]CF3- L-Trp) 
2.2.1 Chemistry 
2.2.1.1 Synthesis of the protected L-Trp derivatives as 
precursor 
2.2.1.1.1 (tert-Butoxycarbonyl)-L-tryptophan (1)  
Di-tert-butyl dicarbonate (4.3 mL, 18.9 mmol) and triethylamine (2.6 mL, 18.9 
mmol) were added to a solution of L-Trp (2.6 g, 12.6 mmol) in MeOH (63 mL) 
successively using syringes, and the mixture was stirred at room temperature under 
an argon atmosphere overnight. The solvent was removed under reduced pressure 
using a rotary evaporator at 30-35C. The colorless oily residue was dissolved in 
EtOAc and washed with water and brine. The reaction mixture was dried over 
anhydrous magnesium sulfate, filtered, and concentrated in vacuo. The crude product 
(3.8 g, 100% yield) was obtained as a colorless oil and used for the next step of the 
synthesis without further purification. (1H NMR, 300 MHz, Acetone-d): δ = 10.04 (s, 
NH), 7.59 (d, J = 6 Hz, 1H), 7.34 (d, J = 6 Hz, 1H), 7.18 (s, 1H), 7.09-6.96 (m, 2H), 
5.91 (d, J = 6 Hz, NH), 4.49 (q, J = 6 Hz, 1H), 3.36-3.13 (m, 2H), 1.33 (s, 9H); (13C 
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NMR, 75 MHz, Acetone-d): δ = 206.43, 174.05, 156.22, 137.47, 128.65, 124.31, 
122.11, 119.54, 119.23, 112.13, 111.05, 79.20, 55.14, 28.47, 28.17. ESI-MS m/z 
calculated for C16H21N2O4+ [M+H]+ 305.15; found 305.35.   
2.2.1.1.2 tert-Butyl (tert-butoxycarbonyl)-L-tryptophan (2)  
Benzyltriethylammonium chloride (2.8 g, 12.2 mmol) and anhydrous potassium 
carbonate (8.4 g, 60.8 mmol) were added to crude 1 (3.7 g, 12.2 mmol) in AcNMe2 
(15 mL), and then 2-bromo-2-methylpropane (14 mL, 122 mmol) was added slowly 
with vigorous stirring at room temperature. The mixture was reacted at 55 °C with 
stirring for 2.5 h and checked by TLC (EtOAc/hexane = 1:4, Rf = 0.3). The reaction 
mixture was quenched by adding chilled water. The precipitate was extracted with 
EtOAc and the organic layer was washed with water two times and with brine one 
time. The organic layer was then dried over anhydrous sodium sulfate, filtered, and 
concentrated in vacuo. The crude product was purified by flash column 
chromatography on silica gel (EtOAc/hexane = 1:7) to afford 2 (2.1 g, 49% yield) as 
a white waxy solid. (1H NMR, 300 MHz, Acetone-d): δ = 10.04 (s, NH), 7.57 (d, J = 
9 Hz, 1H), 7.34 (d, J = 6 Hz, 1H), 7.17-6.97 (m, 2H), 5.90 (d, J = 9 Hz, NH), 4.34 (q, 
J = 6 Hz, 1H), 3.25-3.06 (m, 2H), 1.34 (s, 18H); (13C NMR, 75 MHz, Acetone-d): δ 
= 206.22, 172.25, 156.11, 137.46, 128.63, 124.26, 122.09, 119.46, 119.30, 112.10, 
111.10, 81.28, 79.05, 56.04, 54.96, 28.47, 28.02. ESI-MS m/z calculated for 
C25H36N2O6+ [M+H]+ 361.21; found 361.41. 
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2.2.1.1.3 tert-Butyl (S)-3-(3-((tert-butoxy)-2-((tert-butoxycarbonyl)amino)-3-
oxopropyl)-1H-indol-1-carboxylate (3)  
To a solution of 2 (100 mg, 0.28 mmol) in Me2Cl2 (2.8 mL), di-tert-butyl 
dicarbonate (0.06 mL, 0.28 mmol) and 4-dimethylaminopyridine (3.4 mg, 0.03 mmol) 
were added at room temperature. The reaction mixture was stirred for 10 min and the 
completion of the reaction was checked by TLC (EtOAc/hexane = 1:7, Rf = 0.3). The 
solvent was removed under reduced pressure and the residue was dissolved in EtOAc. 
The organic layer was washed with 1 N HCl and water twice each, dried over 
anhydrous magnesium sulfate, filtered, and concentrated in vacuo. The crude product 
was purified by flash column chromatography on silica gel (EtOAc/hexane = 1:10) 
to afford 3 (128 mg, 99% yield) as a white waxy solid. (1H NMR, 300 MHz, Acetone-
d): δ = 8.01 (d, J = 9 Hz, 1H), 7.50 (d, J = 9 Hz, 1H), 7.40 (s, 1H), 7.21-7.09 (m, 2H), 
5.94 (d, J = 9 Hz, NH), 4.28 (q, J = 6 Hz, 1H), 3.13-2.94 (m, 2H), 1.52 (s, 9H), 1.29 
(s, 9H), 1.25 (s, 9H); (13C NMR, 75 MHz, Acetone-d): δ = 206.11, 171.75, 156.07, 
150.11, 136.20, 131.47, 125.05, 124.81, 123.23, 119.90, 117.13, 115.79, 84.02, 81.71, 
79.17, 55.22, 28.46, 28.16, 28.03. ESI-MS m/z calculated for C25H37N2O6+ [M+H]+ 
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2.2.1.2 Synthesis of bromo L-Trp derivatives as precursor 
2.2.1.2.1 Methyl (S)-3-(2-bromo-1H-indole-3-yl)-2-((tert-
butoxycarbonyl)amino)propanoate (5)  
To a solution of 2-bromo L-tryptophan methyl ester 4 (3.6 g, 9.4 mmol) in MeOH 
(50 mL), di-tert-butyl dicarbonate (5.4 mL, 23.6 mmol) and triethylamine (4.3 mL, 
30.6) were added slowly at room temperature. The solution was stirred at room 
temperature under an argon atmosphere overnight. The solvent was removed under 
reduced pressure, and the residue was dissolved in EtOAc. The organic layer was 
washed with water and brine, dried over anhydrous sodium sulfate, filtered, and 
concentrated in vacuo. The crude product was purified by flash column 
chromatography on silica gel (EtOAc/hexane = 1 : 4) to afford 5 (3.4 g, 46% yield, 2 
steps) as a white solid. (1H NMR, 300 MHz, Acetone-d): δ = 10.69 (s, NH), 7.56 (d, 
J = 6 Hz, 1H), 7.33 (d, J = 6 Hz, 1H), 7.14-7.03 (m, 2H), 6.05 (d, J = 6 Hz, NH), 4.46 
(q, J = 9 Hz, 1H), 3.14 (s, 3H), 3.28-3.12 (m, 2H), 1.34 (s, 9H); (13C NMR, 75 MHz, 
Acetone-d): δ = 206.27, 172.97, 155.89, 137.36, 128.71, 122.69, 120.42, 118.83, 
111.51, 79.35, 54.83, 28.34. ESI-MS m/z calculated for C17H22BrN2O4+ [M+H]+ 
397.08; found 397.33. 
2.2.1.2.2 tert-Butyl (S)-2-bromo-3-(2-((tert-butoxycarbonyl)amino)-3-methoxy-
3-oxopro pyl)-1H-indol-1-carboxylate (6)  
To a solution of 5 (3.4 g, 8.7 mmol) in Me2Cl2 (30 mL), di-tert-butyl dicarbonate 
(2 mL, 8.7 mmol) and 4-dimethylaminopyridine (106 mg, 0.87 mmol) were added at 
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room temperature. The solution was stirred for 10 min and the completion of the 
reaction was checked by TLC (EtOAc/hexane = 1:7, Rf = 0.3). The solvent was 
removed under reduced pressure and the residue was dissolved in EtOAc. The organic 
layer was washed with 1 N HCl and water twice each, dried over anhydrous sodium 
sulfate, filtered, and concentrated in vacuo. The crude product was purified by flash 
column chromatography on silica gel (EtOAc/hexane = 1:10) to afford 6 (4 g, 92% 
yield) as a white waxy solid. (1H NMR, 300 MHz, Acetone-d): δ = 8.03 (d, J = 9 Hz, 
1H), 7.58 (d, J = 6 Hz, 1H), 7.30-7.18 (m, 2H), 6.20 (d, J = 9 Hz, NH), 4.45 (q, J = 9 
Hz, 1H), 3.59 (s, 3H), 3.27-3.12 (m, 2H), 1.66 (s, 9H), 1.28 (s, 9H); (13C NMR, 75 
MHz, Acetone-d): δ = 206.12, 172.62, 164.28, 155.86, 149.49, 137.17, 129.77, 
125.27, 123.66, 119.66, 119.23, 115.78, 110.82, 85.60, 79.32, 53.99, 52.41, 28.36, 
28.17. ESI-MS m/z calculated for C22H30BrN2O6+ [M+H]+ 497.1; found 497.3. 
2.2.1.2.3 (S)-3-(2-Bromo-1-(tert-butoxycarbonyl)-1H-indol-3-yl)-2-((tert-
butoxycarbonyl) amino)propanoic acid (7) 
6 (1 g, 2 mmol) was dissolved in a mixture of tetrahydrofuran 
(THF)/MeOH/water (21 mL, 1:1:1) and the solution was cooled to 0 °C in an ice bath. 
To the solution, lithium hydroxide monohydrate (337 mg, 8 mmol) was added slowly, 
and the reaction mixture was warmed to room temperature. The reaction mixture was 
stirred for 20 min, and the completion of the reaction was checked by TLC 
(Me2Cl2/MeOH = 10:1, Rf = 0.1). The solvent was removed under reduced pressure 
until a precipitate began to form, and the residue was dissolved in EtOAc. The organic 
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layer was washed with 1 N HCl and water twice each, dried over anhydrous sodium 
sulfate, filtered, and concentrated in vacuo. 7 (860 mg, 89%) was obtained as a white 
waxy solid. ESI-MS m/z calculated for C21H28BrN2O6+ [M+H]+ 483.11; found 483.25. 
2.2.1.2.4 tert-Butyl (S)-2-bromo-3-(3-(tert-butoxy)-2-((tert-
butoxycarbonyl)amino)-3-oxopropyl)-1H-indol-1-carboxylate (8) 
Benzyltriethylammonium chloride (0.3 g, 1.3 mmol) and anhydrous potassium 
carbonate (1 g, 7.5 mmol) were added to crude 7 (620 mg, 1.3 mmol) in AcNMe2 (4.3 
mL), and then 2-methyl-2-bromopropane (1.5 mL, 13 mmol) was added slowly with 
vigorous stirring at room temperature. The mixture was heated at 55 °C for 2.5 h, and 
the reaction was checked by TLC (EtOAc/hexane = 1:7, Rf = 0.4). When the reaction 
was completed, the reaction mixture was quenched by adding chilled water. The 
precipitate was extracted with EtOAc, and the organic layer was washed with water 
and brine. The organic layer was dried over anhydrous sodium sulfate, filtered, and 
concentrated in vacuo. The crude product was purified by flash column 
chromatography on silica gel (EtOAc/hexane = 1:10) to afford 8 (300 mg, 43% yield) 
as a white waxy solid. (1H NMR, 300 MHz, Acetone-d): δ = 8.04 (d, J = 6 Hz, 1H), 
7.64 (d, J = 6 Hz, 1H), 7.31-7.19 (m, 2H), 6.12 (d, J = 6 Hz, NH), 4.36 (q, J = 9 Hz, 
1H), 3.23-3.08 (m, 2H), 1.66 (s, 9H), 1.31 (s, 9H), 1.29 (s, 9H); (13C NMR, 75 MHz, 
Acetone-d): δ = 206.14, 171.40, 156.00, 149.61, 137.32, 129.92, 125.25, 123.69, 
120.24, 119.55, 115.76, 85.61, 81.54, 79.19, 54.71, 28.43, 28.21, 27.97. ESI-MS m/z 
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calculated for C25H36BrN2O6+ [M+H]+ 539.18; found 539.25. HRMS (ESI) for 
C25H35BrN2NaO6+ [M+Na]+ requires 561.1571; found 561.1566. 
2.2.1.3 Synthesis of iodo L-Trp derivatives as precursor 
2.2.1.3.1 Methyl (S)-2-((tert-butoxycarbonylamino)-3-(2-iodo-1H-indole-3-
yl)propanoate (12)  
To a solution of 2-iodo L-tryptophan methyl ester 11 (3 g, 8.9 mmol) in MeOH 
(88 mL) at room temperature, di-tert-butyl dicarbonate (2 mL, 8.9 mmol) and 
triethylamine (1.2 mL, 8.9) were added slowly. The solution was stirred at room 
temperature under an argon atmosphere overnight. The solvent was removed under 
reduced pressure, and the colorless residue was dissolved in EtOAc. The organic layer 
was washed with 1 N HCl and water twice each, dried over anhydrous sodium sulfate, 
filtered, and concentrated in vacuo. The crude product was purified by flash column 
chromatography on silica gel (EtOAc/hexane = 1:4) to afford 12 (2.6 g, 66% yield) 
as a white solid. (1H NMR, 300 MHz, Acetonitrile-d): δ = 10.51 (s, NH), 7.56 (d, J = 
9 Hz, 1H), 7.32 (d, J = 9 Hz, 1H), 7.07-6.97 (m, 2H), 6.05 (d, J = 9 Hz, NH), 4.48 (q, 
J = 9 Hz, 1H), 3.56 (s, 3H), 3.25-3.11 (m, 2H), 1.33 (s, 9H); (13C NMR, 75 MHz, 
Acetonitrile-d): δ = 206.54, 173.15, 156.00, 140.13, 128.67, 122.67, 120.25, 118.67, 
111.56, 79.56, 55.16, 28.65. ESI-MS m/z calculated for C17H22IN2O4+ [M+H]+ 445.06; 
found 445.17. 
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2.2.1.3.2 tert-Butyl (S)-3-(2-((tert-butoxycarbonyl)amino)-3-methoxy-3-
oxopropyl)-2-iodo-1H-indol-1-carboxylate (13)  
To a solution of 12 (2.6 g, 5.9 mmol) in Me2Cl2 (60 mL), di-tert-butyl dicarbonate 
(1.4 mL, 5.9 mmol) and 4-dimethylaminopyridine (71 mg, 0.59 mmol) were added at 
room temperature. The solution was stirred for 10 min, and the completion of the 
reaction was checked by TLC (EtOAc/hexane = 1:7, Rf = 0.3). The solvent was 
removed under reduced pressure and the residue was dissolved in EtOAc. The organic 
layer was washed with 1 N HCl and water twice each, dried over anhydrous sodium 
sulfate, filtered, and concentrated in vacuo. The crude product was purified by flash 
column chromatography on silica gel (EtOAc/hexane = 1:10) to afford 13 (3.1 g, 97% 
yield) as a white waxy solid. (1H NMR, 300 MHz, Acetonitrile-d): δ = 8.02 (d, J = 9 
Hz, 1H), 7.51 (d, J = 9 Hz, 1H), 7.26-7.16 (m, 2H), 5.60 (d, J = 9 Hz, NH), 4.43 (q, 
J = 9 Hz, 1H), 3.62 (s, 3H), 3.22-3.04 (m, 2H), 1.67 (s, 9H), 1.28 (s, 9H); (13C NMR, 
75 MHz, Acetonitrile-d): δ = 206.52, 183.70, 172.38, 164.28, 159.53, 158.92, 157.21, 
152.88, 151.77, 149.90, 119.79, 86.50, 62.04. ESI-MS m/z calculated for 
C22H30IN2O6+ [M+H]+ 545.11; found 545.17. 
2.2.1.3.3 (S)-3-(1-(tert-butoxycarbonyl)-2-iodo-1H-indol-3-yl)-2-((tert-
butoxycarbonyl) amino)propanoic acid (14)  
13 (3.1 g, 5.7 mmol) was dissolved in a mixture of THF/MeOH/water (30 mL, 
1:1:1) and the solution was cooled to 0 °C in an ice bath. To the solution, lithium 
hydroxide monohydrate (1.6 g, 38.1 mmol) was added slowly and the reaction 
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mixture was warmed to room temperature. The reaction mixture was stirred for 20 
min and the completion of the reaction was checked by TLC (Me2Cl2/MeOH = 10:1, 
Rf = 0.1). The solvent was removed under reduced pressure until a precipitate began 
to form, and the residue was dissolved in EtOAc. The organic layer was washed with 
1 N HCl and water twice each, dried over anhydrous sodium sulfate, filtered, and 
concentrated in vacuo. 14 (3 g, 99%) was obtained as a white waxy solid. ESI-MS 
m/z calculated for C21H28IN2O6+ [M+H]+ 531.1; found 531.3. 
2.2.1.3.4 tert-Butyl (S)-3-(3-(tert-butoxy)-2-((tert-butoxycarbonylamino)-3-
oxopropyl)-2-iodo-1H-indol-1-carboxylate (15)  
Benzyltriethylammonium chloride (1.4 g, 6 mmol) and dried potassium carbonate 
(4.1 g, 30 mmol) were added to crude 14 (3.2 g, 6 mmol) in AcNMe2 (20 mL) and 
then, 2-bromo-2-methylpropane (6.8 mL, 60 mmol) was added slowly with vigorous 
stirring at room temperature. The mixture was heated at 55 °C and stirred for 2.5 h. 
The reaction was checked by TLC (EtOAc /hexane = 1:7, Rf = 0.4) and quenched by 
adding chilled water. The precipitate was extracted with EtOAc and the organic layer 
was washed with water and brine. The organic layer was dried over anhydrous sodium 
sulfate, filtered, and concentrated in vacuo. The crude product was purified by flash 
column chromatography on silica gel (EtOAc /hexane = 1:10) to afford 15 (2 g, 58% 
yield) as a white waxy solid. The enantiomeric purity was measured by HPLC using 
a chiral column (Chiralpak ID® prep 5 μm, 10 × 250 mm, eluent: isocratic 5% 
isopropyl alcohol in hexane, wavelength: 280 nm, flow rate: 5 mL/min, retention 
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time : 8.9 min (retention time of D-form : 7.2 min)). (1H NMR, 300 MHz, Acetone-
d): δ = 8.04 (d, J = 9 Hz, 1H), 7.64 (d, J = 9 Hz, 1H), 7.24-7.15 (m, 2H), 6.13 (d, J = 
9 Hz, NH), 4.37 (q, J = 9 Hz, 1H), 3.25-3.10 (m, 2H), 1.67 (s, 9H), 1.31 (s, 9H), 1.27 
(s, 9H); (13C NMR, 75 MHz, Acetone-d): δ = 206.14, 171.40, 155.94, 149.89, 138.82, 
130.86, 126.54, 125.02, 123.36, 119.52, 115.92, 85.67, 81.44, 79.12, 54.96, 28.39, 
28.28, 27.98. ESI-MS m/z calculated for C25H36N2O6+ [M+H]+ 587.16; found 587.19. 
HRMS (ESI) for C25H35IN2NaO6+ [M+Na]+ requires 609.1432; found 609.1430. 
2.2.1.4 Synthesis of non-radioactive standard 
2.2.1.4.1 tert-Butyl (S)-2-((tert-butoxycarbonyl)amino)-3-(2-(trifluoromethyl)-
1H-indol-3-yl)propanoate (16)  
To a solution of 2 (145 mg, 0.4 mmol) in MeOH (2 mL), copper iodide (9.1 mg, 
0.048 mmol) and 40% 1-trifluoromethyl-1,2-benziodoxol-3(1H)-one (Togni’s 
reagent, contains 60% diatomaceous earth) (381 mg, 0.48 mmol) were added at room 
temperature under argon atmosphere. The mixture was heated at 70 °C and stirred for 
2 h. When the reaction was completed, EtOAc (2 mL) and saturated NaHCO3 (5 mL) 
were added, and the mixture was extracted with EtOAc. The organic layer was 
washed with water and brine, dried over anhydrous magnesium sulfate, and filtered. 
After the solvent was removed under reduced pressure, the crude product was purified 
by silica gel column chromatography (EtOAc/hexane = 1:10) to afford 16 as a white 
waxy solid. (86 mg, 50%) (1H NMR, 300 MHz, Acetone-d): δ = 11.00 (s, NH), 7.76 
(d, J = 9 Hz, 1H), 7.42 (d, J = 9 Hz, 1H), 7.25 (t, J = 9 Hz, 1H), 7.11 (t, J = 9 Hz, 1H), 
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6.11 (s, NH), 4.32 (q, J = 9 Hz, 1H) 3.41-3.21 (m, 2H), 1.45 (s, 9H), 1.43 (s, 9H), 
1.26 (s, 9H), 1.25 (s, 9H); (13C NMR, 75 MHz, Acetone-d): δ = 206.18, 171.66, 
156.03, 136.94, 128.51, 121.37, 121.02, 112.89, 81.46, 79.15, 56.31, 28.42, 27.93. 
ESI-MS m/z calculated for C22H30F3N2O4+ [M+H]+ 443.48; found 443.40 
2.2.1.4.2 (S)-2-amino-3-(2-(trifluoromethyl)-1H-indol-3-yl)propanoic acid (17)  
In a 25 mL round bottom flask, 16 (66 mg, 0.15 mmol) was dissolved in Me2Cl2 
(1.5 mL) under an argon atmosphere. Dimethyl sulfide (1.5 mL, 20.8 mmol) and 1,2-
ethanedithiol (0.155 mL, 1.85 mmol) were added, and the solution was cooled to 0 °C 
using an ice-water bath. Trifluoroacetic acid (1.5 mL, 20 mmol) was added slowly, 
and the solution was allowed to warm to room temperature. After stirring the solution 
for 48 h, the completion of the reaction was checked by HPLC (XTerra®  RP18 5 μm, 
4.6 × 100 mm, eluent: 0.1% TFA in water; acetonitrile increased from 0% to 100% 
over 30 min, wavelength: 280 nm, flow rate: 1 mL/min, RT: 10.2 min). The solvent 
and volatiles were removed under reduced pressure and the residue was dissolved in 
2 mL of water. The mixture was purified by preparative HPLC (XTerra® prep 10 μm, 
10 × 250 mm, eluent: 0.1%TFA in water; acetonitrile increased from 0% to 100% 
over 30 min, wavelength: 280 nm, flow rate: 5 mL/min, RT: 13.9 min). 17 was 
obtained as a white solid after lyophilization (36 mg, 86%). (1H NMR, 300 MHz, 0.5 
M DCl in D2O): δ = 7.68 (d, J = 9 Hz, 1H), 7.53 (d, J = 9 Hz, 1H), 7.41 (t, J = 9 Hz, 
1H), 7.26 (t, J = 9 Hz, 1H), 4.33 (t, J = 9 Hz, 1H), 3.55-3.36 (m, 2H); (13C NMR, 300 
MHz, 0.5 M DCl in D2O): δ = 171.52, 136.36, 127.05, 125.78, 121.66, 120.11, 113.39, 
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109.58, 54.08, 25.54. ESI-MS m/z calculated for C12H12F3N2O2+ [M+H]+ 273.08; 
found 273.28. HRMS (ESI) for C12H12F3N2O2+ [M+H]+ requires 273.0845; found 
273.0846. 
 
2.2.2 General Procedure for [18F]trifluoromethylation for 
optimization of the labeling conditions 
Irradiated [18F]fluoride in 18O-enriched water was unloaded from the target by He 
flow and captured using an ion-exchange resin (QMA light Sep-Pak cartridge, Waters) 
that was pre-activated using 5 mL of 0.5 M KHCO3 and 10 mL of distilled water. The 
captured [18F]fluoride was released using 0.7 mL of a K222/K2CO3 solution (prepared 
from Kryptofix 222 (181 mg, 0.48 mmol) and K2CO3 (29 mg) in 8.5 mL of MeCN 
and 1.5 mL of water) or 0.075 M tetrabutylammonium bicarbonate solution into the 
vial. The eluted solution was dried at 100 °C, and azeotropic drying was performed 
twice with anhydrous acetonitrile (1 mL).  
To the dried [18F]fluoride, a solution of precursor 3, 8, or 15, copper iodide (CuI), 
methyl chlorodifluoroacetate (MCDFA), and tetramethylethylenediamine (TMEDA) 
in DMF was added, and the reaction mixture was vigorously mixed. The reaction vial 
was sealed with Teflon and heated at 150 °C for 15 min. After completion of the 
reaction, the vial was cooled to room temperature. The [18F]trifluoromethylation 
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labeling efficiency was measured with ITLC-SG using 95% acetonitrile in water as 
the eluent.  
 
2.2.3 Radiosynthesis 
To increase the product radioactivity and to reduce the radiation exposure, the 
radiosynthesis of [18F]CF3- L-Trp was performed in a TRACERLab FX-FN module 
(GE Medical Systems, Germany).  
[18F]Fluoride from the cyclotron was eluted into a reaction vial using 0.7 mL of a 
K222/K2CO3 solution, and the solvent was evaporated by N2 purging. To the reaction 
vial, a solution of 15 (5.3 mg, 0.009 mmol), CuI (5.1 mg, 0.027 mmol), MCDFA (6 
μL, 0.054 mmol), and TMEDA (8 μL, 0.054 mmol) in 180 μL of DMF was added. 
The reaction was mixed and heated at 150 °C for 15 min. To remove the protecting 
groups, 2.4 mL of 1 N HCl was added at room temperature, and the reaction mixture 
was heated at 110 °C for 10 min. Purifications were performed using preparative 
HPLC (XTerra® prep 10 μm, 10 × 250 mm, eluent: 0.3% AcOH in water; EtOH 
increased 0% to 20% from 0 to 20 min, from 20% to 100% from 20 to 25 min, and 
remained at 100% from 25 to 30 min, wavelength: 280 nm, flow rate: 6 mL/min, 
retention time: 13.9 min). The purified product was neutralized with 200 μL of 
NaHCO3, normal saline was added to adjust its isotonicity, and it was filtered through 
a sterile Millex® -FG filter (Merck Millipore, U.S.A.) for injection. Its radiochemical 
purity and molar activity were measured using analytical HPLC (XTerra®  RP18 5 
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μm, 4.6 × 100 mm, 17% acetonitrile in 0.1% TFA in water, isocratic from 0 to 10 
min, wavelength: 280 nm, flow rate: 1 mL/min, retention time: 4.9 min).    
 
2.2.4 Stability test 
To measure the serum stability of [18F]CF3-L-Trp, a solution with the same 
composition used for injection (7% EtOH in normal saline) was prepared. The 
prepared solution (185 kBq, 10 µL) was mixed with human or mouse serum (100 µL), 
and the mixtures were incubated in a shaking incubator at 37 °C. The stability of 
[18F]CF3-L-Trp in human or mouse serum was determined using ITLC-SG (eluent: 
80% EtOH, Rf of [18F]CF3-L-Trp = 0.8–1 and Rf of free [18F]fluoride = 0–0.2) at 0, 30, 
and 60 min and 2, 4, and 6 h. 
 
2.2.5 Serum protein binding assay 
The degree of serum protein binding of [18F]CF3-L-Trp was measured using gel 
filtration as previously reported.36,37 To prevent non-specific binding, the PD-10 
columns were treated with 1% bovine serum albumin (BSA) in 0.1 M DTPA (1 mL) 
and washed with deionized water (50 mL) and phosphate buffered saline (PBS) (30 
mL). Labeled [18F]CF3-L-Trp (185 kBq, 10 µL) was mixed with human or mouse 
serum (100 µL), and the mixtures were then incubated in a shaking incubator at 37 °C 
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for 10 and 60 min. At 10 and 60 min, each mixture was loaded onto the 
preconditioned PD-10 columns (n = 3). The PD-10 columns were eluted with PBS (1 
mL), and thirty fractions were collected in test tubes. The radioactivity of each 
collected fraction was measured using a γ-scintillation counter (18F, 400-1200 keV), 
and the presence of protein in each fraction was confirmed using Coomassie blue 
staining. The percentage of serum protein binding of [18F]CF3-L-Trp was calculated 
from the radioactivity of the fractions. 
 
2.2.6 Biodistribution study 
0.1 mL of [18F]CF3-L-Trp or [18F]CF3-D-Trp (185 kBq) was intravenously injected 
into male BALB/c mice (4-5 weeks old, n = 4 in each group, 18±1 g) without 
anesthesia. For blind testing, each group of mice was randomly selected after 
injection and sacrificed at 10, 60, or 120 min. Blood was obtained from the carotid 
artery, and the other organs were separated immediately. After the blood and other 
organs were weighed, the radioactivity of each organ was determined using a ɤ-
scintillation counter. The results are expressed as the percentage of injected dose per 
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2.2.7 [18F]CF3-L-Trp PET acquisition in rats (n=3 at each time 
point) 
Male Sprague-Dawley (SD) rats (8 weeks), weighing between 250 and 315 g, were 
anesthetized with 2% (v/v) isoflurane at 1 L/min oxygen flow and were intravenously 
injected with prepared [18F]CF3-L-Trp (199±10 MBq). At 5, 10, 20, 40 and 80 mins 
after [18F]CF3- L-Trp injection, the rats were sacrificed by CO2 gas and the brain was 
extracted and washed with normal saline. Extracted brain was positioned in the 
imaging chamber. PET and T2-weighted images were taken by simultaneous 
PET/MRI scanner. Static data were acquired at energy window 400-700 KeV for 20 
min. PET images were reconstructed automatically using Sophia software and 
analyzed using amide program. T2-weighted MR images were acquired for brain 
anatomy and were reconstructed to DICOM using aspect imaging program. 
 
2.2.8 Autoradiography in rats 
Male Sprague-Dawley rats (8 weeks) weighing between 250 g and 330 g were 
used in the experiments. The radiochemical purity and chiral purity of the [18F]CF3-
L-Trp used for injection was over 99%. Purified [18F]CF3-L-Trp (330 MBq, 120 μg) 
was injected into the rats through the tail vein without anesthesia. The rats were 
sacrificed 10 min after the injection of [18F]CF3-L-Trp. The brain was dissected and 
kept in a pre-cooled container with dry ice. Coronal brain sections 30 μm in thickness 
were obtained using a cryostat microtome (Leica CM 1800, Leica Inc., Germany) and 
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thaw-mounted on glass slides. The slides were exposed to a BAS-IP MS 2040E 
imaging plate, and the rat brain autoradiograms were obtained using a Bio-imaging 
Analyzer System (FLA-2000, FUJIFILM Inc., Japan). 
 
Preparation of standards for quantification  
Standards were prepared for each experiment to quantify the specific areas of 
ingestion in the brain. Gelatin (2 g) (Sigma-Aldrich, U.S.A.) was dissolved in distilled 
water (10 mL) and the solution was incubated overnight at 60 °C in water bath the 
night before. Purified [18F]CF3-L-Trp (37 MBq/mL) was serially diluted with distilled 
water to prepare standard solutions with different concentrations. Each standard 
solution (200 μL) was added to the gelatin solution (800 μL) and mixed carefully to 
avoid the formation of air bubbles. The gelatin standard solutions were taken up in 1 
mL syringes, and the syringes were placed in a freezer for 15 min. The cured standard 
solutions in the syringes were removed from the syringe, cut to a suitable size, fixed 
with frozen section compound (FSC 22®  Clear, Leica Inc., Germany), and sliced to a 
30 μm thickness. The sliced standards were thaw-mounted on glass slides, and the 
slides were exposed to the imaging plate simultaneously with the brain slides.  
 
2.2.9 Metabolites study  
Non-radioactive CF3-L-Trp (5 mg, 0.2 mL of water) was administered by 
intravenous injection without anesthesia, and male BALB/c mice (5 weeks, 23±1 g) 
were sacrificed by decapitation at 10 or 60 min. After sacrificing the mice, the whole 
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brain, blood, and urine were removed and stored on ice. The whole brain was 
homogenized (Polytron PT3000, Kinematica, Westbury, Canada) in 10 volumes (w/v) 
of 0.1 M perchloric acid (HClO4) containing 10 mg/mL sodium bisulfite and 1 mM 
EDTA. The homogenate was centrifuged at 3300 rpm for 10 min at 4 °C, and the 
resulting supernatant was filtered through a 0.2 μm polyvinylidene fluoride (PVDF) 
filter (Whatman™, U.K.). The blood sample was centrifuged at 3300 rpm for 10 min 
at 4 °C to separate the plasma, and a protein-free sample was obtained from the 
plasma by adding 5 M HClO4 (30 μL). The mixture was then mixed for 15 s, 
centrifuged at 3300 rpm for 10 min, and filtered as described above. The urine sample 
(0.2 mL) was diluted with 0.1% TFA in water (0.5 mL) and filtered as described above. 
The synthesized major metabolites, 5-hydroxy-CF3-L-tryptophan (CF3-HTP) and 
CF3-serotonin, were prepared by electrophilic substitution using Togni’s reagent and 
were used as references (RT of CF3-HTP : 20.0 min, RT of CF3-serotonin : 15.3 min).  
The metabolites from the brain, blood, and urine were analyzed using HPLC 
(XTerra®  RP18 5 μm, 4.6 × 100 mm, eluent: 0.1% TFA in water; acetonitrile 
increased from 0% to 30% from 0 to 50 min; from 30% to 100% from 50 to 51 min; 
and isocratic at 100% from 51 to 60 min, wavelength: 280 nm, flow rate: 1 mL/min) 
and LC-MS (LTQ velos spectrometer, Thermo Fisher Scientific, U.S.A.). The mass 
spectra (m/z) of the major metabolites were analyzed using the LTQ velos mass 
spectrometer. 
 





2.3.1.1 Synthesis of iodo D- or L-AMT derivatives as precursor 
2.3.1.1.1 2-(tert-butoxycarbonylamino)-3-(1H-indol-3-yl)-2-methylpropanoic 
acid (19)  
To a solution of α-methyl-DL-tryptophan (2 g, 9.2 mmol) in MeOH (31 mL) at 
room temperature under argon atmosphere, di-tert-butyl dicarbonate (3.2 mL, 13.7 
mmol) and Et3N (2.6 mL, 18.3) was added slowly. The reaction mixture was stirred 
overnight and concentrated in vacuo. The crude product 19 was obtained as a yellow 
waxy solid and used for next step without any purification. (1H NMR, 300 MHz, 
Acetone-d): δ = 10.06 (s, 1H), 7.56 (d, J=9 Hz, 1H), 7.30 (d, J=9 Hz, 1H), 7.10 (s, 
1H), 7.00 (t, J=9 Hz, 1H), 6.91 (t, J=9 Hz, 1H), 5.77 (s, 1H), 3.41 (s, 2H), 1.52 (s, 
3H), 1.39 (s, 9H); (13C NMR, 75 MHz, Acetone-d): δ = 206.15, 176.20, 155.31, 
137.19, 129.63, 125.14, 121.86, 119.80, 119.46, 111.97, 60.61, 28.62  
2.3.1.1.2 tert-Butyl 2-(tert-butoxycarbonylamino)-3-(1H-indol-3-yl)-2-
methylpropanoate (20)  
To a mixture of crude 19 (929 mg, 2.9 mmol), benzyltriethylammonium chloride 
(665 mg, 2.9 mmol) and dried potassium carbonate (2.02 g, 14.6 mmol) in N,N-
- 47 - 
 
dimethylacetamide (3 mL), t-Butyl bromide (3.3 mL, 29.2 mmol) was added slowly 
with vigorous stirring at room temperature under argon atmosphere. The reaction 
mixture was heated at 55oC for 2.5 hr and quenched by 350 mL of cold water which 
was cooled down in refrigerator before 30 mins. Precipitates were extracted with 
EtOAc and the organic layer was washed with water and brine. The reaction mixture 
was dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The 
crude product was purified by flash column chromatography on silica gel 
(EtOAc/Hex = 1:4) afford 20 (536 mg, 49% yield in 2 steps) as a colorless waxy solid. 
(1H NMR, 300 MHz, Acetone-d): δ = 7.56 (d, J= 9 Hz, 1H), 7.33 (d, J=9 Hz, 1H), 
7.1 (s, 1H), 7.05 (t, J=9 Hz, 1H), 6.95 (t, J=9 Hz, 1H), 5.81 (s, 1H), 3.22-3.47 (dd, 
J1=15 Hz, J2=45 Hz), 1.42 (s, 9H), 1.40 (s, 12H); (13C NMR, 75 MHz, Acetone-d): δ 
= 206.21, 174.24, 155.26, 137.12, 129.74, 125.09, 121.83, 119.86, 119.38, 111.93, 
81.04, 60.78, 28.67, 28.03. ESI-MS m/z calculated for C21H31N2O4+ [M+H]+ 375.48 
found 375.36 
2.3.1.1.3 tert-Butyl 3-(3-tert-butoxy-2-(tert-butoxycarbonylamino)-2-methyl-3-
oxopropyl)-1H-indol-1-carboxylate (21)  
   To a solution of 20 (306 mg, 0.82 mmol) in acetonitrile (1.6 mL), di-tert-butyl 
dicarbonate (0.47 mL, 2 mmol) and 4-dimethylaminopyridine (20 mg, 0.16 mmol) 
was added at room temperature under N2. The reaction mixture was stirred for 15 
mins and completion of the reaction was checked by the TLC. The solvent was 
removed under reduced pressure and the residue was dissolved with EtOAc. The 
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organic layer was washed with 1 N HCl and water two times respectively, dried over 
anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The 
crude product was purified by flash column chromatography on silica gel 
(EtOAc/Hex = 1:7) to afford 21 (390 mg, 99% yield) as a colorless waxy solid. (1H 
NMR, 300 MHz, Acetone-d): δ = 8.10 (d, J=9 Hz, 1H), 7.59 (d, J=9 Hz, 1H), 7.40 (s, 
1H), 7.24(t, J=9 Hz, 1H), 7.15 (t, J=9 Hz, 1H), 5.91 (s, 1H), 3.25-3.45 (dd, J1=15 Hz, 
J2=30 Hz, 2H), 1.63 (s, 9H), 1.44 (s, 12H), 1.43 (s, 9H); (13C NMR, 75 MHz, Acetone-
d): δ = 205.96, 173.83, 155.19, 150.11, 135.88, 132,58, 125.55, 124.80, 123.09, 
120.47, 116.81, 115.61, 84.02, 81.49, 60.43, 28.23, 28.04, 27.88 ESI-MS m/z 
calculated for C26H39N2O6+ [M+H]+ 475.60 found 475. 
2.3.1.1.4 (S)-tert-Butyl 3-(3-tert-butoxycarbonylamino)-2-methyl-3-oxopropyl)-
2-iodo-1H-indole-1-carboxylate (22a)  
   Mercury trifluoroacetate (167 mg, 0.39 mmol) was added at room temperature 
under Ar to a solution of 21 (143 mg, 0.3 mmol) in DCM (2 mL). The reaction 
mixture was stirred for 30 mins and washed with sat KI solution. The organic layer 
was dried over sodium sulfate and filtered. To the reaction mixture, iodine (114 mg, 
0.45 mmol) was added and the reaction mixture was stirred another 3 hrs under argon 
atmosphere. The reaction mixture was quenched by 10% sodium sulfite, washed with 
water and brine, dried over anhydrous magnesium sulfate and filtered. After 
concentrated under reduced pressure, the crude product was purified by silica gel 
column chromatography with eluent. (E.A/Hex = 1:20 ~ 1:10). The chiral mixture 
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was purified by chiral preparative HPLC (ChiralpakID® prep 5 μm, 10 mm × 250 mm 
Eluent: 2.5% isopropyl alcohol in n-hexane). 22a was eluted at 11.3 min and obtained 
as a colorless waxy solid after concentration in vacuo. (74 mg, 41%) (1H NMR, 300 
MHz, Acetone-d): δ = 8.01 (d, J=9 Hz, 1H), 7.50 (d, J=9 Hz, 1H), 7.17 (t, J=9 Hz, 
1H), 7.09 (t, J=9 Hz, 1H), 6.01 (s, 1H), 3.22-3.67 (dd, J1=15 Hz, J2=105 Hz), 1.68 (s, 
9H), 1.44 (s, 21H); (13C NMR, 75 MHz, Acetone-d): δ = 206.09, 173.91, 155.73, 
149.96, 138.90, 131.92, 127.22, 124.91, 123.16, 120.53, 115.59, 85.71, 80.84, 61.09, 
28.30, 28.25, 28.04; HRMS (ESI) for C26H37IN2NaO6+ [M+Na]+ requires 623.4755 
found 623.1585; [α]D20 = -0.4 (c=1.0, CH3Cl) 
2.3.1.1.5 (R)-tert-Butyl 3-(3-tert-butoxycarbonylamino)-2-methyl-3-oxopropyl)-
2-iodo-1H-indole-1-carboxylate (22b)  
   Mercury trifluoroacetate (167 mg, 0.39 mmol) was added at room temperature 
under argon atmosphere to a solution of 21 (143 mg, 0.3 mmol) in DCM (2 mL). The 
reaction mixture was stirred for 30 mins and washed with saturated potassium iodide 
solution. The organic layer was dried over sodium sulfate and filtered. To the reaction 
mixture, iodine (114 mg, 0.45 mmol) was added and the reaction mixture was stirred 
another 3 hrs under argon atmosphere. The reaction mixture was quenched by 10% 
sodium sulfite, washed with water and brine, dried over anhydrous magnesium sulfate 
and filtered. After concentrated under reduced pressure, the crude product was 
purified by silica gel column chromatography with eluent. (E.A/Hex = 1 : 20 ~ 1 : 
10). The chiral mixture was purified by chiral preparative HPLC (ChiralpakID® prep 
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5 μm, 10 mm × 250 mm Eluent: 2.5% isopropyl alcohol in n-hexane). 22b was eluted 
at 9.9 min and obtained as a colorless waxy solid after concentration in vacuo. (73 
mg, 40.5%) (1H NMR, 300 MHz, Acetone-d): δ = 8.01 (d, J=9 Hz, 1H), 7.50 (d, J=9 
Hz, 1H), 7.17 (t, J=9 Hz, 1H), 7.09 (t, J=9 Hz, 1H), 6.01 (s, 1H), 3.22-3.67 (dd, J1=15 
Hz, J2=105 Hz), 1.68 (s, 9H), 1.44 (s, 21H); (13C NMR, 300 MHz, Acetone-d): δ = 
206.09, 173.91, 155.73, 149.96, 138.90, 131.92, 127.22, 124.91, 123.16, 120.53, 
115.59, 85.71, 80.84, 61.09, 28.30, 28.25, 28.04; HRMS (ESI) for C26H37IN2NaO6+ 
[M+Na]+ requires 623.4755 found 623.1585; [α]D20 = +0.4 (c=1.0, CH3Cl) 
2.3.1.2 Synthesis of non-radioactive standard 
2.3.1.2.1 (R,S)-tert-butyl-2-(tert-butoxycarbonylamino)-2-methyl-3-(2-
(trifluoromethyl)-1H-indol-3-yl)propanoate (23)  
   To a solution of 20 (260 mg, 0.69 mmol) in MeOH (3.5 mL), Copper iodide (26 
mg, 0.14 mmol) and 40% Togni’s reagent (654 mg, 0.83 mmol) was added at room 
temperature under argon atmosphere. The reaction mixture was heated at 70oC for 2 
hrs and diluted with EtOAc (2 mL) followed by the addition of sodium 
hydrogencarbonate (5 mL). The crude product mixture was extracted using EtOAc 
and the organic layer was washed with water and brine respectively. The reaction 
mixture was dried over anhydrous magnesium sulfate and filtered. After the solvent 
was removed under reduced pressure, the crude product was purified by silica gel 
column chromatography (E.A/Hex = 1:10). 23 was obtained as a colorless waxy solid 
after concentration in vacuo. (150 mg, 49%) (1H NMR, 300 MHz, Acetone-d): δ = 
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10.99 (s, 1H), 7.65 (d, J=9 Hz, 1H), 7.40 (d, J=9 Hz, 1H), 7.22 (t, J=9 Hz, 1H), 7.03 
(t, J=9 Hz, 1H), 3.35-3.81 (dd, J1=15 Hz, J2=96 Hz), 1.45 (s, 9H), 1.43 (s, 9H), 1.24 
(s, 3H); ESI-MS m/z calculated for C22H30F3N2O4+ [M+H]+ requires 443.48 found 
443.40 
2.3.1.2.2 (R,S)-2-carboxy-1-(2-(trifluoromethyl)-1H-indol-3-yl)propan-2-
aminium 2,2,2-trifluoroacetate (24)  
   In a 25 mL of round bottom flask, 23 (46 mg, 0.1 mmol) was dissolved with DCM 
(1 mL) under argon atmosphere. Dimethyl sulfide (1 mL, 14 mmol) and 1,2-
ethanedithiol (1 mL, 1.4 mmol) was added and the reaction mixture was cooled down 
to 0oC using ice-water bath. Trifluoroacetic acid (1 mL, 13.5 mmol) was slowly added 
and the reaction mixture was allowed to reach room temperature where it was stirred 
for 48h. After completion of reaction by monitoring with HPLC, the volatiles were 
removed under reduced pressure and the residue was dissolved with 2 mL of water. 
The mixture was purified with preparative HPLC (XTerra® prep 10 μm, 10 × 250 mm, 
Eluent: 0.1%TFA in water; CH3CN increased for 0% to 100% for 30 min at 5 
mL/min). 24 was eluted at 9.3 min and obtained as a white solid after lyophilization 
(25 mg, 88%). (1H NMR, 300 MHz, 0.5 M DCl in D2O): δ = 7.40 (d, J=9 Hz, 1H), 
7.26 (d, J=9 Hz, 1H), 7.13 (t, J=9 Hz, 1H), 6.98 (t, J=9 Hz, 1H), 3.13-3.45 (dd, J1=6 
Hz, J2=15 Hz), 1.41 (s, 9H); (13C NMR, 300 MHz, 0.5 M DCl in D2O): δ = 197.99, 
160.11, 151.47, 149.58, 145.47, 144.64, 137.14, 132.23, 85.21, 55.83, 45.81; HRMS 
(ESI) for C13H14F3N2O2+ [M+H]+ requires 287.1002 found 287.0995; 
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2.3.2 Radiosynthesis 
Proton beam irradiated 18O-enriched water to produce [18F]fluoride by 18O(p,n)18F 
reaction using the 16.5 Mev- cyclotron (PETtrace 10, GE healthcare, Uppsala, 
Sweden). Irradiated [18F]fluoride in 18O-enriched water was unloaded from target by 
He flow and captured by ion-exchange resin (QMA light Sep-Pak cartridge, waters) 
which was pre-activated by 5 mL of 0.5 M K2CO3 and 10 mL of distilled water. 
Captured [18F]fluoride was released by 0.7 mL of K222/K2CO3 solution (prepared from 
kryptofix 222 (181 mg, 0.48 mmol) and K2CO3 (29 mg) in 8.5 mL of CH3CN and 1.5 
mL of water) or 0.075 M tetrabutylammonium bicarbonate solution into the vial. The 
eluted solution was dried at 100℃ and azeotropic drying was performed twice with 
anhydrous acetonitrile (1 mL).  
To the vial, a solution of 22a or 22b with copper(I) iodide (Cu(I)I), methyl 
chlorodifluoroacetate (MCFDA) and tetramethylethylenediamine (TMEDA) in N,N-
Dimethylformamide (DMF) was added and vigorously mixed using vortex. The vial 
was sealed with Teflon and heated at 150oC for 15 minutes. The vial was removed 
from heating and cooled in a cold water bath for 5 minutes. For the remove of 
protection groups, 2.4 mL of 1 N HCl was added via syringe without needle and 
heated at 110oC for 10 minutes. [18F]trifluoromethylation labeling efficiencies were 
monitored by ITLC-SG using 95% CH3CN in water as eluents. 
   All the radiosynthesis of [18F]CF3-L-AMT or [18F]CF3-D-AMT for the 
autoradiography was performed in a TRACERLab FX-FN module (GE medical 
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Systems, Germany). 10.8 mg of precursors with 11 mg of Cu(I)I, 9 μL of MCFDA 
and 13.5 μL of TMEDA in 0.3 mL of DMF were used. All the other conditions were 
same as in the manual. Purifications were performed using a preparative HPLC 
(XTerra® prep 10 μm, 10 × 250 mm, Eluent : 0.3% AcOH in water; CH3CN  
increased for 0% to 20% from 0 to 20 min 20% to 100% from 20 to 25 min 100% for 
5 min at 7 mL/min). The purified solution of radiolabeled compound was neutralized 
by NaHCO3, diluted with normal saline and filtered through a sterile Millex® -FG 
filter (Merck Millipore, USA) for injection. 
 
2.3.3 Stability test 
   To measure the in vitro stabilities of [18F]CF3-L-AMT, we prepared the same 
compositions of [18F]CF3-L-AMT with the solutions for injection. The solutions were 
stored at room temperature for 6 h and analyzed by ITLC-SG (eluents: 80% EtOH). 
For the serum stability test, 25 µL of the prepared solutions were mixed with 325 µL 
of human serum or mouse serum and incubated at 37oC for 6 h. When the 
radioactivity was measured, ethanol was added to serum mixture and centrifuged 
(3,000 rpm) for 5 min to precipitate the serum proteins. The supernatant of the 
mixture was analyzed in the same way as previously. 
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2.3.4 Biodistribution (in mice) 
   0.1 mL of [18F]CF3-L-AMT or [18F]CF3-D-AMT (50 kBq/mL) was intravenously 
injected into male BALB/c mice (4-5 weeks old, n = 4 in each group, 18±1 g) without 
anesthesia. For blind testing, each group of mice were randomly selected after 
injection and sacrificed at 10, 60, or 120 min. Blood was obtained from the carotid 
artery and other organs were separated immediately. After blood and other organs 
were weighed, the radioactivity of each organs were counted using a ɤ-scintillation 
counter. Results are expressed as the percentage of injected dose per gram of tissue 
(%ID/g). Values are expressed as the mean±SD. 
 
2.3.5 Autoradiography (in rat) 
 Male Sprague-Dawley rats (8-10 weeks), weighing between 250 g and 330 g, 
were used in the experiments. They were kept in our animal facility (22-24 oC, 8 a.m. 
to 8 p.m. day and night cycle) and provided food and water ad libitum. The food was 
prohibited at least 16 hour before the experiment but water was provided ad libitum. 
All the rats were injected between 4 to 6 p.m. to avoid the effect of circadian rhythm. 
All the experimental procedures were approved by Institutional Animal Care and Use 
Committee at Seoul National University Hospital.  
Radiochemical purity and chiral purity of [18F]CF3-L-AMT or [18F]CF3-D-AMT 
for injection were over 99%. Purified [18F]CF3-L-AMT or [18F]CF3-D-AMT (175-395 
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MBq, 40-140 μg) were injected into rats through tail vein without anesthesia. The rats 
were killed at 5, 10, 20 40 80 min post-injection of [18F]CF3-L-AMT and at 10, 20, 
40, 80 min post injection of [18F]CF3-D-AMT. The brain were dissected and kept in 
the pre-cooled container with dry ice. 30 μm thickness of coronal brain sections were 
obtained using cryostat microtome (Leica CM 1800, Leica Inc., Germany) and thaw-
mounted on glass slides. The slides were exposed to BAS-IP MS 2040E imaging 
plates and rat brain autoradiograms were obtained by Bio-imaging Analyzer System 
(BAS-2500) 
Standard Preparation. To quantify the brain-specific region of ingestion, we 
prepared the 18F standard in all single experiments. 2 g of jelatin (Sigma-Aldrich) was 
dissolved in distilled water and the solution was incubated at 60oC in water bath for 
overnight in a previous day of experiment. Purified [18F]CF3-L-AMT or [18F]CF3-D-
AMT (Range: 5-12 MBq/mL) was diluted with distilled water to make 1 mL solution 
and the solution was serially diluted in duplicate. Serial diluted solution was added to 
800 μL of jelatin solution and the standard solutions were carefully mixed not to make 
air bubbles. After placed in a freezer for 15 min, hardened standard solutions were 
sliced 30 μm thickness and thaw-mounted on glass slides. The standard solution slides 
were exposed to the imaging plated at the same time as the brain slides. 
   Lithium treatment model. Lithium treated rat model was devised to evaluate the 
difference brain distribution of [18F]CF3-L-AMT between normal and serotonin 
metabolism enhanced SD rats. Lithium chloride (LiCl) was dissolved in water and 
the solution was administered 2 times at 10AM and 5 PM per day for 5 days (85 
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mg/kg, i.p.). Li-treated rats deprived of food 16 h before experiment and water was 
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3 RESULTS AND DISCUSSION 
3.1 [18F]Trifluoromethyl- L-tryptophan ([18F]CF3- L-Trp) 
3.1.1 Chemistry 
We synthesized a protected L-Trp 3 and its 2-bromo 8 and 2- iodo derivatives 15 
as precursors for the [18F]trifluoromethylation of the 2-position of Trp. 3 was 
synthesized via a three-step synthetic process in which the amines and carboxylic acid 
were protected by Boc and tert-butyl ester, respectively (Scheme 1).  
SCHEME 1 Synthesis of protected L-Trp (3). Reagents and conditions: a) (Boc)2O, Et3N, 
MeOH, RT, overnight, 100%; b) (CH3)3C-Br, K2CO3, BTEAC, DMAC, 55°C, 2.5 h, 49%; c) 
(Boc)2O, DMAP, DCM, RT, 15 min, 99%.   
 
The bromo precursor 8 was synthesized via the introduction of bromine at the 2-
position by electrophilic substitution using N-bromosuccinamide (NBS) according to 
a previously reported procedure (Scheme 2).26 4 was synthesized from commercially 
available L-Trp methyl ester under acidic conditions; no other regioisomers were 
detected. As in the synthesis of precursor 3, both the primary and indole amine were 
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protected by Boc to give 6 in quantitative yield. The methyl ester was replaced with 
the tert-butyl ester to be removed in one-step acid hydrolysis in the final step of 18F-
labeling.   
SCHEME 2 Synthesis of bromo precursor (8). Reagents and conditions: a) N-
bromosuccinimide (NBS), AcOH/HCO2H (4 : 1, v/v), RT, 20 min; b) (Boc)2O, Et3N, MeOH, 
RT, overnight, 46% (2 steps); c) (Boc)2O, DMAP, DCM, RT, 10 min, 92%; d) LiOH 
monohydrate, THF/MeOH/H2O (1 : 1 : 1, v/v), 0°C to RT, 20 min, 89%; e) (CH3)3C-Br, 
K2CO3, BTEAC, DMAC, 55°C, 2.5 h, 43%.  
 
The iodo precursor 15 was synthesized by regioselective 2-iodination via Pd-
cyclometalation, iodine insertion, and ligand exchange (Scheme 3). Iodo L-Trp 
methyl ester 11 was purified by simple filtration. The yield of the iodination after Boc 
protection and purification of intermediate 12 through a four-step process was 
calculated and found to be quite high (66%). 15 was then synthesized using a method 
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similar to that depicted in Scheme 2. The D-enantiomer of 15 was also synthesized 
from the commercially available D-Trp methyl ester. The chiral purity of 15 and its 
isomer were evaluated using HPLC with a chiral column, and no racemization was 
detected (Figure 5).    
Non-radioactive CF3-Trp 17 was prepared as a reference material of [18F]CF3-L-
Trp (Scheme 4). The high electron density at the 2-positon of the indole ring enabled 
the introduction of the trifluoromethyl group by electrophilic substitution.38 The 
protecting groups were removed by TFA and the radical scavenger dimethyl sulfide 
and 1,2-ethanedithiol, and purification of 17 was performed using HPLC. The yield 
was 89% based on the isolated product after lyophilization. 
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SCHEME 3 Synthesis of bromo precursor (15). Reagents and conditions: a) Pd(OAc)2, 
MeCN, RT, 48 h; b) I2, MeOH, RT, 2.5 h; c) 1,10-phenanthroline monohydrate, DCM, RT, 
4 h; d) (Boc)2O, Et3N, MeOH, RT, overnight, 66% (4 steps); e) (Boc)2O, DMAP, DCM, RT, 
10 min, 97%; f) LiOH monohydrate, THF/MeOH/H2O (1 : 1 : 1, v/v), 0°C to RT, 20 min, 
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SCHEME 4 Synthesis of non-radioactive standard (17). Reagents and conditions: a) 
Cu(I)I, Togni’s reagent (contains 60% diatomaceous earth), MeOH, 70°C, 2 h, 50%; 
b) TFA, HSCH2CH2SH, (CH3)2S, 0°C to RT, 48 h, 86%. 
 
 
FIGURE 5. HPLC chromatograms of racemic mixture of protected iodo precursor (15) 
(A), L-form of protected iodo precursor (15a) (B) and D-form of protected iodo precursor 
(15b) (C). Blue: UV (280 nm). Chromatograms were obtained on a Diacel Chiral pak ID 
column. Mobile phase was 2.5% Isopropyl alcohol in n-Hexane and flow rate was 5 ml/min. 
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3.1.2 Optimization of the [18F]trifluoromethylation conditions 
In this study, we synthesized enantiopure [18F]CF3-L-Trp with the same chiral 
center as natural tryptophan. Protected tryptophan with different functional groups at 
2-position (3, 8, and 15) were investigated for Cu(I)-mediated 
[18F]trifluoromethylation. Essentially, the [18F]trifluoromethylation reaction requires 
an aromatic compound activated by a halogen residue as a precursor.30,31 However, 
the halogen-free 3 could also be used as a precursor via direct C-H functionalization 
due to the high electron density of indole at the 2-position. Thus, we tested the 
labeling efficiency of the [18F]trifluoromethylation reaction using these three 
precursors. 
We first optimized the conditions for [18F]trifluoromethylation on the 2-position 
of the indole ring 
(Table 1). When the amine of the indole was not protected, the radiochemical yield 
(RCY) was very low (4%), demonstrating the importance of the amine protecting 
group (entry 1). The RCY increased when a protected precursor was used (10%) 
(entry 2). The synthesized precursors 3, 8, and 15 were subjected to 
[18F]trifluoromethylation on the 2-position of the indole ring to determine the most 
appropriate leaving group. The iodo precursor 15 showed the highest RCY for 
[18F]trifluoromethylation (56%) (entry 4), the bromo precursor 8 the second highest 
(22%) (entry 3), and the protonated precursor 3 the lowest (10%). The RCY of 15 
was 5.5 times and 2.5 times higher than that of 3 and 8, respectively. Then, we further 
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tested the use of different amounts of substrate 15 (entry 4-6). When 5 μmol (2.7 mg) 
of 15 was used, the RCY was higher than when 2.5 μmol (1.4 mg) was used (34%). 
However, the RCY did not increase further when 9 μmol (5.3 mg) of 15 was used 
(54%). When the amount of the reagents MCDFA or TMEDA was increased, a sludge 
was formed (entry 7). Decreased amounts of MCDFA and TMEDA resulted in 
decreased RCY (30%) (entry 8). Since the labeling synthesis took place at 150 °C, a 
solvent with a higher boiling point, DMSO, was tried. However, in DMSO, the 
reaction did not proceed at all (0%) (entry 9). When the phase transfer catalyst was 
changed from K222/K2CO3 to tetrabutylammonium bicarbonate (TBAB), no 
significant difference was observed (50%, entry 10).  
 
TABLE 1. [18F]trifluoromethylation reaction using various precursors.  
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a) RCY (%) was measured by radio-TLC;  
b) Reaction mixture became sludge;  
c) [
18



















1 H H 5 5.1 mg 6 μL 8 μL DMF 4 
2 Boc H 5 5.1 mg 6 μL 8 μL DMF 10 
3 Boc Br 5 5.1 mg 6 μL 8 μL DMF 22 
4 Boc I 5 5.1 mg 6 μL 8 μL DMF 56 
5 Boc I 9 5.1 mg 6 μL 8 μL DMF 54 
6 Boc I 2.5 5.1 mg 6 μL 8 μL DMF 34 
7 Boc I 5 5.1 mg 12 μL 16 μL DMF -b 
8 Boc I 5 5.1 mg 3 μL 4 μL DMF 30 
9 Boc I 5 5.1 mg 3 μL 4 μL DMSO 0 
10c Boc I 5 5.1 mg 3 μL 4 μL DMF 50 
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3.1.3 Automatic radiosynthesis 
The automatic radiosynthesis of [18F]CF3-L-Trp for subsequent in vitro 
characterization and for further animal experiments was using an FX-FN automation 
module (Scheme 5). Compared to manual synthesis, the amounts of the iodo 
precursor 15, the other reagents, and solvent were doubled for the automatic synthesis, 
since the reaction vessel was larger. For the removal of the protection groups, aqueous 
1 N HCl was used instead of TFA. The residue after synthesis could be removed 
cleanly using water and acetone not to damage the automation module. The 
synthesized [18F]CF3-L-Trp was purified using prep-HPLC. The total synthesis time 
was 70 min including purification, and the RCY of [18F]CF3-L-Trp was 6±1.5% based 
on the isolated product (Figure 6).  
The purified [18F]CF3-L-Trp was analyzed using analytical HPLC, and the 
retention time of [18F]CF3-L-Trp in the chromatogram was consistent with that of non-
radioactive CF3-L-Trp. The radiochemical purity of [18F]CF3-L-Trp was greater than 
99%, and no other peaks were detected. 
We could achieve enough high molar activity (0.44-0.76 GBq/μmol) for 
metabolic imaging of [18F]CF3-L-Trp. The enantiomeric purity was also determined 
using analytical HPLC with a chiral column, which confirmed no racemization 
occurred (Figure 7). 
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SCHEME 5. Radiosynthesis of [18F]CF3-L-Trp. Reagents and conditions: a) 
K222/K2CO3 or TBAB, CuI, MCDFA, TMEDA, DMF, 150°C, 15 min; b) aq 1N HCl, 
110°C, 10 min. 
 
 
FIGURE 6. HPLC chromatograms of reaction mixrue of [18F]CF3-L-Trp for 
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FIGURE 7. Analytical HPLC chromatograms of non-radioactive CF3-Trp (A) 
and radioactive [18F]CF3-L-Trp (B) after purification. Chromatograms were 
obtained by (A) UV (280 nm) (B) radioactivity detection. 
 
3.1.4 Stability test 
Prior to in vivo application, we performed in vitro characterization of [18F]CF3-L-
Trp. Decomposition of [18F]CF3-L-Trp increases non-specific accumulation and has 
an undesirable effect on brain PET imaging. Stability studies of [18F]CF3-L-Trp were 
performed in the prepared medium (7% ethanol) at room temperature for 6 h, and in 
mouse or human serum at 37 °C for 6 h. [18F]CF3-L-Trp did not degrade at all in the 
7% ethanol solution, which indicated that it can be stored at room temperature at least 
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for 6 h. In mouse or human serum, less than 3% of the decomposed product was 
detected over the entire time period investigated (Figure 8).  
 














37 C , H u m a n  s e ru m
37 C , M o u s e  s e ru m
R o o m  te m p e ra tu re
 
FIGURE 8. Stability test results of [18F]CF3-L-Trp. [18F]CF3-L-Trp was incubated 
with human and mouse sera at 37 °C and with 7% EtOH at room temperature.   
 
3.1.5 Serum protein binding assay 
Serum protein binding was measured by incubating [18F]CF3-L-Trp in mouse or 
human serum at 37 °C for 10 and 60 min and subsequently separating the free and 
bound fractions by gel filtration. The separated fractions were analyzed using a 
gamma counter, and the protein-bound percentages were calculated using the 
measured radioactivity values. [18F]CF3-L-Trp showed low binding to human and 
mouse serum protein: 0.12% and 0.26% to human serum protein at 10 and 60 min, 
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respectively, and 0.1% and 0.34% to mouse serum protein at 10 and 60 min, 
respectively (Table 2). Thus, the majority of [18F]CF3-L-Trp would be present as the 
free form in blood, which could favor its transport into the brain via amino acid 
transporters.  
 
TABLE 2. Protein bound fractions (%) of [18F]CF3-L-Trp in human and mouse sera 
at 37C. 
 
Protein bound (%) 
Human serum Mouse serum 
10 min 
0.12 ± 0.01 0.10 ± 0.00 
60 min 
0.26 ± 0.03 0.34 ± 0.02 
 
 
3.1.6 Biodistribution study 
The systemic distribution of [18F]CF3-L-Trp was investigated in BALB/c mice at 
10 and 60 min after intravenous injection through the tail vein (Table 3). The 
enantiomer [18F]CF3-D-Trp was also studied simultaneously for comparison rather 
than using a blocking agent such as 2-amino-2-norbornanecarboxylic acid (BCH).  
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The uptake of [18F]CF3-L-Trp (2.06 ± 0.22% ID/g) was significantly higher than 
that of [18F]CF3-D-Trp (0.48 ± 0.04% ID/g) at 10 min in the mouse brain (p < 0.01). 
This result suggests that [18F]CF3-L-Trp can penetrate BBB via the L-type amino acid 
transport system (LAT).  
Muscle, heart, and bone also showed significantly higher uptakes of [18F]CF3-L-
Trp than [18F]CF3-D-Trp (p < 0.01) at 10 min. These results also indicate the specific 
uptake of L-form amino acids in these tissues through the LAT. The higher uptakes of 
[18F]CF3-L-Trp in brain, muscle, and bone were persistent until 1 h.  
However, in blood, the radioactivity of [18F]CF3-D-Trp (3.48 ± 0.24% ID/g) was 
significantly higher than that of [18F]CF3-L-Trp (2.75 ± 0.09% ID/g) at 10 min. The 
high blood activity of [18F]CF3-D-Trp was attributed to its lower uptake in various 
tissues. [18F]CF3-D-Trp showed significantly higher uptake in the spleen and lungs at 
10 min, which also indicated that the high blood activity contributed to radioactivity 
in blood-rich organs such as the spleen and lungs.  
Both tracers showed the highest uptake level in the kidney at 10 min (10.33 ± 
0.93% ID/g for [18F]CF3-L-Trp and 11.31 ± 1.17% ID/g for [18F]CF3-D-Trp). The bone 
uptakes of [18F]CF3-L-Trp were 6.80 ± 0.74 and 9.34 ± 0.62% ID/g at 10 and 60 min, 
respectively, and were significantly higher than that of [18F]CF3-D-Trp (p < 0.01) at 
all the investigated time points. The high radioactivity in bone indicated the 
possibility of in vivo defluorination. The degree of in vivo defluorination was 
considered to be higher for [18F]CF3-L-Trp than [18F]CF3-D-Trp. 
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TABLE 3. Results of the biodistribution study of [18F]CF3-L-Trp and [18F]CF3-
D-Trp in normal BALB/c mice. Data are % ID/g tissue (mean ± SD, n = 4) 
Isomer L D 
Tissue 10 min 60 min 10 min 60 min 
Blood 
2.75 ± 0.09** 0.59 ± 0.10 3.48 ± 0.24 0.55 ± 0.06 
Muscle 
1.52 ± 0.03** 0.88 ± 0.11** 0.89 ± 0.11 0.42 ± 0.04 
Brain 
2.06 ± 0.22** 0.43 ± 0.08** 0.48 ± 0.04 0.24 ± 0.01 
Heart 
3.19 ± 0.20** 0.58 ± 0.10 1.94 ± 0.20 0.72 ± 0.24 
Lung 
2.59 ± 0.19** 0.67 ± 0.16 3.42 ± 0.21 0.60 ± 0.05 
Liver 
3.35 ± 0.09 0.68 ± 0.16* 3.82 ± 0.37 0.38 ± 0.05 
Spleen 
2.88 ± 0.07** 0.47 ± 0.05 3.85 ± 0.28 0.49 ± 0.06 
Stomach 
2.58 ± 0.32 0.40 ± 0.16 2.80 ± 0.42 0.38 ± 0.09 
Intestine 
3.02 ± 0.20 1.08 ± 0.15 2.88 ± 0.38 1.00 ± 0.24 
Kidney 
10.33 ± 0.93 2.05 ± 0.27** 11.31 ± 1.17 0.86 ± 0.15 
Bone 
6.80 ± 0.74** 9.34 ± 0.62** 3.54 ± 0.57 2.69 ± 0.29 
Depicted p values (2-tail t-test) refer to differences between the L- and D-isomers. *p 
< 0.05; **p < 0.01. 
 
3.1.7 PET/MR study in rats (n=3 at each time point) 
Static PET/MR images were obtained at 5, 10, 20, 40 and 80 mins after 
intravenous administration of [18F]CF3-L-Trp into Sprague-Dawley rats. Whole brain 
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activities were plotted with time and The whole-brain radioactivity peaked at 10 min 
and then decreased (Figure 8A). PET/MR images at 10 min showed wide distribution 
of [18F]CF3-L-Trp in the rat brain (Figure 8B) and the distribution pattern was 
different with other known serotonin synthesis imaging PET agent. In particular, the 
uptake of raphe nucleus (dorsal and medial), which are known to be present in the 
cell body of serotonergic neurons was comparatively very low. Instead, pineal gland, 
thalamus, hypothalamus and midbrain showed particularly high uptake. Pineal gland 
metabolize serotonin to melatonin to modulate sleep patterns and other regions were 
known to be present in terminal nerves of serotonergic neurons and serotonin 
transporter (SERT). However, the distribution pattern in the brain alone could not 
demonstrate the involvement of [18F]CF3-L-Trp in serotonin metabolism, the low 
uptake in raphe nucleus, and the state of [18F]CF3-L-Trp in the brain.  
The specific uptake regions of [18F]CF3-L-Trp in the rat brain could not be clearly 
distinguished from adjacent regions due to the low spatial resolution of micro PET 
system. In addition to brain uptake, high radioactivity was accumulated in bone 
because of the in vivo defluorination of [18F]CF3-L-Trp. Another PET tracer 7-
[18F]fluorotryptophan also showed the highest radioactivity in pineal gland and also 
high uptake in serotonergic neuron rich regions like dorsal raphe nucleus and 
hypothalamus.23 On the other hand, [18F]CF3-L-Trp showed faster wash out than 7-
[18F]fluorotryptophan from those regions, which represents the rapid excretion of it 
from the neuronal cells or inhibited reuptake of it into the neuronal cells. 





FIGURE 9. PET/MR imaging of [18F]CF3-L-Trp in SD rats (n=3 at each time 
point). Static data was acquired at 5, 10, 20, 40 and 80 mins. (A) Whole brain 
activities were plotted with time after intravenous administration of [18F]CF3-L-Trp 
(199±10 MBq). (B) Representative brain images were simultaneously obtained at 10 
min after intravenous administration of [18F]CF3-L-Trp (204 MBq). SUV: 
Standardized uptake value, defined as activity (MBq/mL) within the volume of 
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3.1.8 Autoradiography 
We then performed autoradiography, which provides higher spatial resolution 
images than PET, to observe the distribution pattern of [18F]CF3-L-Trp in the rat brain 
more clearly (Figure 10). Based on the results of the PET studies, the autoradiography 
time using [18F]CF3-L-Trp was set to 10 min after injection, since the uptake of 
[18F]CF3-L-Trp in the brain was highest at 10 min.  
 
FIGURE 10. Brain autoradiography of [18F]CF3-L-Trp in a rat brain. The SD rat 
was sacrificed 10 min after intravenous injection of [18F]CF3-L-Trp (328 MBq). 
Frozen sections with a thickness of 30 m were obtained by cryostat microtome, and 
autoradiograms were obtained using BAS imaging plates. Some of the structures 
clearly visualized include the (1) thalamus, (2) hypothalamus, (3) hippocampus 
(dorsal), (4) parietal cortex, (5) mammillary body, (6) hippocampus (ventral), (7) 
medial geniculate nucleus (8) occipital cortex (9) pineal body (10) superior colliculus 
(11) dorsal raphe nucleus, and (12) medial raphe nucleus. 
 
The distribution pattern of [18F]CF3-L-Trp was related to the serotonergic neurons. 
The highest accumulation of [18F]CF3-L-Trp was observed in the pineal gland (5.41% 
- 75 - 
 
ID/g). The pineal gland is an endocrine gland that modulates the sleep pattern by 
producing melatonin from serotonin. Other serotonergic-neuron-rich brain regions 
such as the parietal cortex, hippocampus (ventral and dorsal), mammillary body, 
thalamus, hypothalamus, and raphe nucleus (dorsal, medial) also showed high 
uptakes. Relatively low uptake of [18F]CF3-L-Trp was observed in the white matter. 
Another autoradiography study using a serotonergic agent [14C]AMT also reported 
high accumulation in pineal gland.39 Similarly with [18F]CF3-L-Trp, [14C]AMT also 
accumulated in caudate, parietal cortex, thalamus, hypothalamus, hippocampus, and 
mamillary body, that was consistent with this study. However, high uptake in dorsal 
raphe nucleus was not found unlike with [14C]AMT.39 
 
3.1.9 Metabolites study 
To investigate whether CF3-L-Trp is metabolized to CF3-5-HTP or CF3-serotonin 
by tryptophan hydroxylase, non-radioactive CF3-L-Trp was injected into normal 
BALB/c mice through the tail vein, and the metabolites of CF3-L-Trp in the brain, 
blood, and urine were analyzed using HPLC at 10 and 60 min post-injection (Figure 
11). In the chromatograms, the CF3-serotonin peaks had relative areas of 9% and 31% 
in the brain at 10 and 60 min, respectively, and the CF3-5-HTP peak was not detected 
(Figure 11B). Thus, CF3-L-Trp was metabolized into CF3-serotonin by serotonin 
metabolism in serotonergic system. However, as with [11C]AMT, it was limited to 
provide the absolute serotonin synthesis rate due to the presence of large portion of 
unmetabolized CF3-L-Trp in the brain.  
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A CF3-tryptamine peak with a slightly shorter retention time than and a similar 
area to that of the CF3-serotonin peak was observed at 60 min in the brain. It could 
be synthesized by decarboxylation of CF3-L-Trp. The CF3-serotonin peaks in the 
blood had relative areas of 7% and 78% at 10 and 60 min, respectively. No CF3-5-
HTP peak was found in the blood (Figure 11C). Only the CF3-L-Trp peak was 
observed in the urine (Figure 11D). The mass spectrum (m/z) of the CF3-serotonin 
metabolite peak was recorded using LTQ mass spectrometry, and the ESI-MS positive 
ion of CF3-serotonin was found at m/z 245.25 (calculated m/z of C11H12F3N2O+: 
245.23) (Figure 12). A higher level of CF3-serotonin was detected in the blood than 
in the brain because the circulating platelets lead to increased serotonin uptake.40 
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FIGURE 11. HPLC chromatograms of CF3-L-Trp metabolites in BALB/c mice 
at 10 and 60 min. The chromatograms show (A) the synthesized standards; and 
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FIGURE 12. Mass spectra of CF3-serotonin metabolite. The sample was obtained 



















SCHEME 6. Synthesis of precursors (22a and 22b) and non-radioactive 
standard. Reagents and conditions: a) (Boc)2O, Et3N, MeOH, RT, overnight, 99%; 
b) (CH3)3C-Br, K2CO3, BTEAC, DMAC, 55°C, 2.5 h, 49%; c) (Boc)2O, DMAP, 
DCM, RT, 15 min, 99%; d) Hg(OTf)2, I2, KI, DCM (1:1), RT, 41%, e) CuI, Togni’s 
reagent (contains 60% diatomaceous earth), MeOH, 70°C, 2 h, 48%; f) TFA, 
HSCH2CH2SH, (CH3)2S, 0°C to RT, 48 h, 88%. 
 
- 80 - 
 
Synthesis of L- or D-iodo AMT (I-AMT) as precursor is shown in scheme 6. We 
used commercially available racemic (R,S)-AMT for starting material. Enantiopure 
AMT was very expensive and during the reactions, it could be racemized to make the 
other enantiomer. Since the primary amine or carboxylic acid decreases the 
radiolabeling efficiency of [18F]trifluoromethylation30, both groups should be 
protected not to influence the reactivity for radiolabeling. For simple and fast removal 
of protection groups under a mild condition after labeling, we protected primary 
amine at α-position with t-butoxycarbonyl (Boc) group to afford 19 in 99% yield. 
After removal of solvent, the tert-butyl esterification was performed in a same 
reaction RBF without purification (20, 49%). Because the amine in the indole ring 
also could affect the labeling efficiency, we protected the secondary amine with Boc 
group using 4-dimethylaminopyridine (DMAP). After reaction, we could remove 
DMAP easily in a work-up using aq 1 N HCl to yield 21. (99%) 
To radiolabel [18F]trifluoromethylation, arenes or heteroarenes need to be 
activated with iodine for the cross-coupling. Even if the carbon on 2 position of indole 
ring can be labeled without any functionalization, radiolabeling efficiency of 
[18F]trifluoromethylation was under 10% which was not sufficient to apply for the 
further experiments. Therefore, the iodination at 2 position of indole ring was 
necessary to obtain higher radiolabeling efficiency and not to make other 
regioisomers. 
At first we tried palladium(II) mediated iodination to introduce iodine at 2 positon 
of indole ring without racemization27. But this method required multi steps and we 
- 81 - 
 
could not use the enantioprue AMT for the starting material. So we tried mercury(II) 
mediated iodination. This method was only single step and could be applied to the 
protected AMT 21. With this method, the intermediates purification steps were not 
needed except for NMR or Mass spectrometry assay.  
Tyrptophan has two enantiomers, the naturally occurring L-tryptophan and the 
artificially synthesized D-tryptophan, and mainly the natural L-tryptophan isomer 
penetrate the BBB. We expected that [18F]CF3-AMT would have similar character. 
Therefore, the synthesis of L-isomer is required to prevent the undesired radiation 
exposure. Since the I-AMT is racemic mixtures, we have to separate the mixture into 
the each enantiomer. Conventional method to prepare the enantiomer is using the 
chiral auxiliary but it needs extra steps, introduction and removal of the auxiliary. 
Moreover, the other enantiomer still remains even after purification. To solve the 
problems and to save the time and cost, we used simple HPLC purification method 
using chiral column. The mobile condition was 2.5% IPA in n-Hex, so it was easy. 
And the retention time of 22a and 22b were sufficient to be purified to 9.9 min and 
11.3 min (Figure 13). 
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FIGURE 13. HPLC chromatograms of racemic mixture of protected I-AMT (22) 
(A), L-isomer of protected I-AMT (22a) (B) and D-isomer of protected I-AMT 
(22b) (C). Blue: UV (280 nm). Chromatograms were obtained on a Diacel Chiralpak 
ID column. Mobile phase was 2.5% Isopropyl alcohol in n-Hexane and flow rate was 
5 ml/min. 
 
   Non-radioactive CF3-AMT 7 was synthesized by electrophilic substitution using 
togni’s reagent38 (Scheme 6). The intermediate was the same as that for synthesizing 
precursor and trifluoromethyl group was easily displaced to the 2 position of indole 
ring (23, 48%). Previous experience with removing the protection groups of 2-
fluorotryptophan has led to a careful attempt to deprotect Boc and t-butyl ester. We 
tried TFA/radical scavengers combination to afford standard compound41. We used 
- 83 - 
 
dimethyl sulfide and 1,2-ethanedithiol as scavengers, and unlike 2-fluorotryptophan, 
no significant degradation was detected in preparative HPLC chromatography. After 
lyophilization, we obtained white solid of 24 in yield of 88%. 
 
3.2.2 Radiosynthesis 
   It was difficult to introduce [18F]fluorine itself at 2 position of indole ring due to 
the high electron density and stability. To increase the availability of [18F]labeled 
tryptophan, we tried copper(I) mediated [18F]trifluoromethylation by cross coupling. 
We want to apply the [18F]trifluoromethylation for the late stage, but it was reported 
that free amine and carboxylic acid decrease the radiolabeling efficiency in the 
previous research. So, using protected 2-iodo AMT, we optimized the condition for 
[18F]trifluoro methylation at 2 position of indole ring (Table 4). The drawback of this 
method is to use large amount of precursor and yield the low specific activity of 
[18F]trifluoromethylated compound. Even if the molar activity of tracer for 
metabolism imaging is not crucial comparing to the receptor imaging, 24 could block 
the transport of [18F]CF3-AMT into the brain. To increase the molar activity, we tried 
the different condition of labeling reaction to find out the minimal amount of 
precursor and 2.7 mg of precursor was sufficient to yield [18F]25a or [18F]25b in 
manual (Entry 2). After labeling, we tried deprotection of Boc groups in a one-pot 
reaction using acid such as 4 N HCl in 1,4-dioxnae, trifluoroacetic acid (TFA) or aq 
1 N HCl. When we use 4 N HCl in 1,4-dioxane under room temperature, we found 
out the indole was easily broken. On the other hand, TFA or aq 1 N HCl could remove 
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the protection groups not making significant degradation of indole ring. TFA was not 
proper to use in the Fx-Fn automation module due to the corrosive vapor. 
   For the preclinical studies in practical, we set up the condition for labeling in the 
Fx-Fn automation module (Scheme 7). We increased the amount of 22a or 22b (10.8 
mg, 18 µmol), MCFDA (9 µL), TMEDA (13.5 µL) and DMF (300 µL) in the module 
and obtained the protected [18F]25a or [18F]25b in over 50% yield by ITLC. The 
reaction temperature would be good at 150oC. When the temperature was increased, 
DMF was dried soon and when the temperature was decreased, the labeling efficiency 
was decreased. For the last, the reaction time over 15 min could not help to increase 
the labeling efficiency. As in manual, aq 1 N HCl worked successfully in one-pot 
reaction. On the other hand, HCl in organic solvent, such as methanol, made it 
difficult to purify [18F]CF3-L-AMT or [18F]CF3-D-AMT by the all compounds coming 
together on the preparative HPLC system. We used 0.3% acetic acid buffer and 
ethanol and the purified solution of [18F]CF3-L-AMT or [18F]CF3-D-AMT involved in 
17~18% ethanol. To neutralize the pH and decrease the portion of ethanol for 
injection, we added 8.4% NaHCO3 into the solution and it was diluted with normal 
saline. We checked pH of the solution was ~7 by pH paper and controlled ethanol 
content was under 10%. Gas chromatography confirmed that the amount of organic 
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TABLE 4. Optimization of the amount of substrate and reagents or reaction solvent 












CuI MCDFA TMEDA 
1 1.4 11 mg 6 μL 9 μL DMF 35.4 
2 2.7 11 mg 6 μL 9 μL DMF 72.1 
3 5.4 11 mg 6 μL 9 μL DMF 65.7 
4 2.7 11 mg 12 μL 16 μL DMF -
c
 
6 2.7 11 mg 6 μL 9 μL DMSO 0 
Solvent volume was 200 μL; b) RCC(%) was measured based on the ITLC (95% 
CH3CN);Reaction solution became slugge; MCDFA : Methyl chlorodifluoroacetate, 
TMEDA : N,N,N,N-Tetramethylethylenediamine. 
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SCHEME 7. Radiosynthesis of [18F]CF3-L-AMT. Reagents and conditions: a) 
K222/K2CO3 or TBAB, CuI, MCDFA, TMEDA, DMF, 150°C, 15 min; b) aq 1N HCl, 
110°C, 12 min. 
 
   We took the analytical HPLC chromatogram of [18F]CF3-L-AMT after 
purification and the retention time was 7.2 min, which was similar to the non-
radioactive standard 24 (Figure 14a). According to the Figure 14b, the radiochemical 
purity was over 99% and no other radioactive or non-radioactive compounds were 
detected. To measure the molar activity of [18F]CF3-L-AMT, we draw standard curve 
with 5 different concentrations of 24. The molar activity was 1188±248 MBq/μmol 
(n=9) after purification and 880±270 MBq/μmol (n=12) for injection which was 
higher than the molar activity of [11C]AMT (55mCi/mmol)42. As the time passed by, 
the molar activity was decreased, we did all animal studies as fast as possible. It is 
also important to confirm the enantiomeric purity of prepared product. Because L-
form mainly penetrate the BBB43 to image the serotonergic system, D-form may give 
the additional radiation exposure. We tried several kinds of chiral columns but only 
chiralpak® WH column which was packed with amino acid derivative and copper(II) 
complex could separate the each enantiomer completely. We checked the 
enantiomeric purity of [18F]CF3-L-AMT or [18F]CF3-D-AMT after purification and 
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the retention time was 13.8 and 43.5 min respectively (Figure 15). No racemization 





FIGURE 14. Analytical HPLC chromatograms of the non-radioactive standard 
24 (A) and [18F]CF3-L-AMT (B) after purification. Chromatograms were obtained 
by UV (280 nm) (A) and radioactivity (B).   
- 88 - 
 
 
FIGURE 15. HPLC chromatograms of racemic mixture of the non-radioactive 
standard (24) (A), radioactive [18F]CF3-L-AMT (B), and [18F]CF3-D-AMT (C). 
Blue: UV (280 nm), Red: Radioactivity. Chromatograms were obtained on a Diacel 
Chiral pak WH column. Mobile phase was 10 mM CuSO4 and MeOH (9:1) and flow 
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3.2.3 Stability test 
   Before applying [18F]CF3-L-AMT into the in vivo system, in vitro stability tests 
in human and mouse serum at 37oC and in prepared medium at room temperature 
were performed. We checked the stability at 0, 0.5, 1, 2, 4, 6 h and during the period 
no significant degradation form was detected in all conditions. It indicates that the 
[18F]CF3-L-AMT could be stored at room temperature for 6 h prior to injection and 
would not make any radioactive degraded compounds which influence the brain 
uptake of [18F]CF3-L-AMT in serotonergic system. 
 
3.2.4 Biodistribution (in mice)  
   We investigated the biodistribution using [18F]CF3-L-AMT or [18F]CF3-D-AMT 
in brain, blood, and 9 organs at 10, 60, and 120 min after injection in normal BALB/c 
mice (Table 5). It was helpful to evaluate the distribution in the whole body as well 
as the brain for understanding the characteristics and radiation exposure in each 
organs. The main excretory pathway of both tracers was found to be through the 
kidney (25.49±1.86% ID/g for [18F]CF3-L-AMT and 36.89±5.54% ID/g for [18F]CF3-
D-AMT at 10 min). Similar to the results of autoradiography, biodistribution study 
showed that the initial uptake of [18F]CF3-L-AMT in brain (2.27±0.14% ID/g) was 
much higher than that of [18F]CF3-D-AMT (0.34±0.03% ID/g). These results 
confirmed that L-isomer can be applied to serotonin metabolism through the BBB by 
LAT and that the penetration of the BBB of D-isomer is limited by the transporter. 
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Significant amount of radioactivity was found in bone using [18F]CF3-L-AMT 
(4.70±0.27% ID/g at 10 min and 4.12±0.35% ID/g at 120 min) compare [18F]CF3-D-
AMT (2.92±0.31% ID/g at 10 min and 1.47±0.14% ID/g at 120 min). Similar to 
[18F]CF3-Trp, in vivo defluorination of L-isomer was significantly higher than D-
isomer. This means that [18F]fluoride was released mainly by the enzymatic 
metabolism in [18F]CF3-L-AMT. 
 
TABLE 5. Results of the biodistribution study of [18F]CF3-L-AMT and [18F]CF3-
D-AMT in normal BALB/c mice. Data are expressed by %ID/g tissue (mean ± SD, 
n = 4). 
Tissue Isomer 10 min 60 min 120 min 
Blood 
L 
3.02±0.16** 0.70±0.08 0.22±0.03 
D 
7.35±0.70 0.78±0.07 0.24±0.02 
Muscle 
L 
1.44±0.07 0.92±0.10** 0.56±0.08* 
D 
1.76±0.28 1.16±0.04 0.72±0.05 
Brain 
L 
2.27±0.14** 0.73±0.09** 0.13±0.02** 
D 
0.34±0.03 0.11±0.01 0.04±0.00 
Heart 
L 
3.65±0.34 0.95±0.07** 0.29±0.03** 
D 
3.37±0.55 1.26±0.08 0.54±0.04 
Lung 
L 
3.34±0.22** 0.86±0.26 0.36±0.02* 
D 
6.62±0.42 0.91±0.14 0.29±0.04 




5.95±0.29** 1.11±0.17** 0.32±0.05* 
D 
18.60±1.41 1.65±0.19 0.42±0.06 
Spleen 
L 
4.01±0.26** 0.72±0.12** 0.35±0.13 
D 
5.37±0.64 1.26±0.08 0.45±0.04 
Stomach 
L 
4.28±1.31 0.80±0.08 0.30±0.15 
D 
3.37±0.30 0.85±0.15 0.30±0.05 
Intestine 
L 
4.53±0.37** 1.40±0.09** 0.86±0.14 
D 
3.63±0.23 1.64±0.06 0.91±0.07 
Kidney 
L 
25.49±1.86** 4.14±0.51 1.32±0.38 
D 
36.89±5.54 3.41±0.49 0.94±0.07 
Bone 
L 
4.70±0.27** 4.42±1.70** 4.12±0.35** 
D 
2.92±0.31 1.93±0.21 1.47±0.14 
 
 
3.2.5 Autoradiography (in rat) 
Autoradiography using [18F]CF3-L-AMT or [18F]CF3-D-AMT was performed to 
figure out the specific brain distribution pattern in rat brain. Compared with PET, 
autoradiography could give much higher resolution images. (PET: 1 mm, 
autoradiography: 100 μm)  
We intravenously injected [18F]CF3-L-AMT or [18F]CF3-D-AMT without 
anesthesia due to that it could affect serotonin metabolism and the uptake of tracer in 
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rat brain. The time for injection was between 4 and 6 P.M to avoid the effect of 
circadian rhythm. The rats were fasted the night before the experiment because 
labeled AMT could be competitively inhibited by the amino acid containing in food. 
Water was provided ad libitum not to exert influence on the mood. The uptake in rat 
brain was quantified by using the standard solution44. To obtain the reliable results, 
we made the standard curve on the every single autoradiography and all the standard 
curves had over R2 = 0.99. 
The autoradiograms were obtained 5, 10, 20, 40 and 80 min post injection and 
Figure 16 showed the representative autoradiogram at 20 min. As expected, the whole 
brain uptake of L-isomer in rat (1.13±0.19 %ID/mm2) was 9 times higher than D-
isomer (0.13 %ID/mm2) at 20 min post injection. We also performed 10, 40, 80 min 
as well but the only specific uptake of [18F]CF3-D-AMT in rat brain was shown in the 
cerebral blood and pineal gland (Figure 16b). Unlike other brain regions, pineal gland 
is not isolated from the body by the BBB system. Although we did not perform the 
competition assay using [18F]CF3-AMT and LAT inhibitor, 2-amino-2-
norbornanecarboxylic acid (BCH), we could directly compare the uptake of 
enantiopure L-isomer and D-isomer in rat brain. On the basis of these results, we 
carefully expect that L-isomer could penetrate BBB by L-type amino acid transport 
system (LAT) which is the major route for neutral aromatic amino acids. 
Compared to D-isomer, L-isomer was distributed widely thorough the whole brain 
(Figure 16a). The highest uptake of [18F]CF3-L-AMT (4.56±0.20% ID/mm2) was 
shown in pineal gland which metabolize serotonin to melatonin to modulate sleep 
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patterns in circadian rhythm45,46. As it is known that the rate of serotonin synthesis in 
pineal gland is much higher than in other brain regions14,47, we found dense 
radioactivity in pineal gland. Mammillary bodies had some uptake (1.27±0.45% 
ID/mm2) which are often categorized as part of the hypothalamus and important for 
recollective memory48. Thalamus (1.46±0.08% ID/mm2) and hypothalamus 
(1.86±0.04% ID/mm2) of diencephalon also had distinct distribution of the tracer but 
at 80 min post injection, it was difficult to figure out those regions. Cortex, such as 
frontal or parietal cortex (1.24±0.07% ID/mm2), had mild uptake as well because of 
their cognitive functions which are related with serotonergic system. Hippocampus 
(ventral and dorsal) had similar radioactivity at 20 min (1.24±0.07% ID/mm2 for 
ventral and 1.18±0.16% ID/mm2 for dorsal) but at 40 or 80 min post injection, the 
radioactivity in hippocampus (ventral and dorsal) were relatively increased to 
distinguish with adjacent regions. Hippocampus is related with memory store and 
several subtypes of serotonin receptors are located in the region. Amygdala which is 
limbic areas with hippocampus and related with emotion expression also had the 
similar distribution pattern with hippocampus. Raphe nucleus (dorsal and medial) had 
lower uptake of the tracer than as expected. It is because the cell bodies of 
serotonergic neurons are laid in brainstem raphe nuclei and these neurons are 
projected to many brain regions like cortex, basal ganglia, thalamus, hypothalamus, 
limbic areas like hippocampus and amygdala, etc49.  
 




FIGURE 16. Representative autoradiograms in normal SD rat using [18F]CF3-
L-AMT (A) and [18F]CF3-D-AMT (B). Some of the structures clearly visualized are 
(1) caudate-putamen, (2) thalamus, (3) hypothalamus, (4) hippocampus (ventral), (5) 
amygdala, (6) medial geniculate nucleus, (7) mammillary body, (8) parietal cortex (9) 
hippocampus (dorsal) (10) raphe nucleus (dorsal), (11) raphe nucleus (ventral), (12) 
pineal gland, (13) superior colliculus. Uptake value (MBq/mL/mm2) was defined as 
radioactivity (MBq/mL) within the area of interest. 
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Li-ion is known to stimulate the synthesis of serotonin, which was once used as a 
remedy for psychosis50,51. To evaluate [18F]CF3-L-AMT in the serotonin metabolism 
enhanced model, we treated SD rats with LiCl (85 mg/kg i.p.) 2 times per day for 5 
days52 and the autoradiogram was obtained (Figure 17). The distribution of [18F]CF3-
L-AMT in normal and Li-treated rats were very similar, however the uptake rate and 
clearance from the brain were different. The distribution patterns in normal and Li-
treated SD rats were compared directly with the time-activity curves (TACs) in Figure 
18. In normal rats, the uptake of brain regions, except pineal gland, was peaked at 20 
min and then decreased into the level of background at 80 min. On the other hand, in 
Li-treated rats, the uptake rates were faster about 10 min in almost all brain regions 
and the uptake levels of radioactivity at peak time in some specific brain regions, such 
as mammillary body or hypothalamus were higher than in normal rats. At 80 min 
after injection, the radioactivity level (% ID/mm2) in Li treated rats was remained 2 
times more than in normal rats. The results indicate that the uptake rate of [18F]CF3-
L-AMT was faster and the clearance from the brain was slower in the enhanced 
serotonin metabolism SD rat than in normal SD rat.  
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FIGURE 17. Representative autoradiograms in Li-treated SD rat using 
[18F]CF3-L-AMT. Some of the structures clearly visualized are (1) caudate-putamen, 
(2) thalamus, (3) hypothalamus, (4) hippocampus (ventral), (5) amygdala, (6) medial 
geniculate nucleus, (7) mammillary body, (8) parietal cortex (9) hippocampus (dorsal) 
(10) raphe nucleus (dorsal), (11) raphe nucleus (ventral), (12) pineal gland, (13) 
superior colliculus. Uptake value (MBq/mL/mm2) was defined as radioactivity 
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FIGURE 18. Time-activity curves of [18F]CF3-L-AMT in Li-treated SD rat (A) 
and in normal SD rat (B) at 5, 10, 20, 40, 80 min post-injection (n=2 at each time 
point). Radioactivity was measured in pineal gland, thalamus, hypothalamus, 
hippocampus (ventral), hippocampus (dorsal), parietal cortex, mammillary body, 
raphe nucleus (dorsal), raphe nucleus (medial) and caudate putamen Uptake value 
was defined as radioactivity (MBq/mL) within the area of interest divided by the 
injected dose. 
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TABLE 6. Comparison of the uptake of [18F]CF3-L-AMT in normal and Li-
treated SD rat at 10 and 80 min (n=2 at each time point). Uptake value was defined 
as radioactivity (MBq/mL) within the area of interest divided by the injected dose. 
 
 
3.2.6 Comparison of distribution and metabolism between 
[18F]CF3-L-Trp and [18F]CF3-L-AMT.     
   To evaluate the effect of α-methylation on tryptophan derivative, the whole body 
distribution and analysis of metabolites of [18F]CF3-L-Trp and [18F]CF3-L-AMT were 
compared (Figure 19 and Table 7). Since the fast washout in the brain of [18F]CF3-L-
Trp was difficult to obtain PET images and the serotonin synthesis rate, it was needed 
to develop a labeled tryptophan derivative that could last a long time in the brain as a 
property of the compound itself, not through the drug. Radiochemical and 
enantiomeric purity of prepared tracers were over 99%. At 10 min, the brain uptakes 
of [18F]CF3-L-AMT and [18F]CF3-L-Trp were 2.27 ± 0.14 and 2.06 ± 0.22, 
respectively and the brain uptake of [18F]CF3-L-AMT (0.73 ± 0.08) at 60 min was 
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significantly higher than that of [18F]CF3-L-Trp (0.43 ± 0.08). This result indicated 
that α-methylation increased the retention in the brain by reducing metabolism by 
MAO. The bone uptake of [18F]CF3-L-AMT at 60 min (4.50 ± 0.47) was significantly 
lower than that of [18F]CF3-L-Trp (9.34 ± 0.62), suggesting the lower in vivo 
defluorination of [18F]CF3-L-AMT. Both of the tracers showed high uptakes in the 
kidney. 
 
FIGURE 19. Biodistribtuion of [18F]CF3-L-TRP (A) and [18F]CF3-L-AMT (B) in 
normal BALB/c mice at 10, 60, and 120 min post-injection. Values represent 
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TABLE 7. Comparison of brain, blood, and bone distribution of [18F]CF3-L-Trp 
and [18F]CF3-L-AMT in normal BALB/c mice (n=4). Data are % ID/g tissue (mean 
± SD, n = 4) 
Time 
(min) 














10 2.06±0.22 2.27±0.14 2.75±0.09* 3.02±0.16 6.80±0.74* 4.70±0.27 
60 0.43±0.08* 0.73±0.09 0.59±0.10 0.70±0.08 9.34±0.62* 4.50±0.47 
120 0.17±0.06 0.13±0.02 0.34±0.11 0.22±0.03 8.58±0.91* 4.12±0.35 
 
Depicted p values (2-tail Mann-Whitney test) refer to differences between [18F]CF3-
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4 CONCLUSION 
We successfully synthesized enantiopure [18F]CF3-L-Trp, which might be 
resistant to kynurenine pathway enzymes, such as IDO or TDO. Enantiomeric purity 
could reduce the unnecessary radiation exposure. In PET images and autoradiograms, 
the distribution of [18F]CF3-L-Trp in brain showed high uptake in terminal nerves of 
serotonergic neurons. However, it is not clear that the PET imaging of [18F]CF3-L-Trp 
reflect serotonin metabolism due to the low uptake in raphe nucleus. Metabolites 
study showed that CF3-L-Trp is metabolized into CF3-serotonin by serotonin 
metabolism, but there is a limit to obtain the absolute serotonin synthesis rate because 
a large unmetabolized form remain in the brain. Another problem CF3-L-Trp was that 
rapidly excreted from the brain and did not show any specific brain accumulation. It 
also took the high in vivo defluorination and accumulated in bone. 
Based on the these results, [18F]CF3-L-Trp was not suitable for serotonergic 
system imaging and need to modify to prolong the residence time in the brain and 
reduce in vivo defluorination. To enhance metabolic character of tryptophan 
derivative, α-substituted [18F]CF3-L-AMT was synthesized in the same manner as 
described for synthesis of [18F]CF3-L-Trp. Distribution and metabolite study indicated 
that α-methylation increased the retention of the radiotracer in the brain by reducing 
metabolism by MAO and decreased in vivo defluorination. The low uptake in raphe 
nucleus and high unmetabolized pool of [18F]CF3-L-AMT limited the application of 
this radiotracer for serotonergic system imaging. Nevertheless, experimental data 
suggest that the distribution patterns of [18F]CF3-L-AMT in normal and Li-treated SD 
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rats were related with serotonergic activity and metabolism. Kinetic data may provide 
information about the disease associated with serotonin synthesis but, it needs some 
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 +TOF MS: Exp 1, 0.5158 min from Sample 1 (KimH_sample2) of KimH_sample2.wiff
a=7.02082230998623150e-004, t0=-4.28806580931386240e-001 (DuoSpray ())
Max. 4.5e5 cps.
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 +TOF MS: Exp 1, 0.4224 min from Sample 1 (KimH_sample1) of KimH_sample1.wiff
a=7.02081117720926560e-004, t0=-4.18220791534452960e-001 (DuoSpray ())
Max. 1.0e5 cps.
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국 문 초 록 
 
 
18F-표지 트립토판 유도체를 이용한  
세로토닌 대사 PET 영상제 개발 
 






세로토닌 신경계는 우울증, 사회적 불안 장애 및 간질과 같은 중추 
신경계의 다양한 기능 장애와 연관이 있다. 그러므로 세로토닌의 합성을 
영상화할 수 있는 방사성 프로브의 개발은 그러한 질병의 진단에 
중요하다. α-[11C]메틸트립토판 ([11C]AMT)은 세로토닌 합성 영상에 이용 
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가능한다. 그러나 [11C]AMT 의 뇌 내 섭취는 세로토닌 대사 뿐만 아니라 
키뉴레닌 대사 또한 반영할 수 있으므로 잘못된 정보를 제공할 수 있다. 
또한 트립토판은 뇌에서 빠르게 제거되기 때문에 뇌에서의 머무름 
시간을 연장시키고 모노 아민 산화 효소 (MAO)에 의한 대사를 
감소시키기 위해 α-메틸화가 필요하다. 본 연구에서는 구리(I)를 매개로 
한 [18F]트리플루오로메틸화를 이용해 인돌 고리의 2 번 위치에 18F을 
표지하여 세로토닌 대사만을 반영할 수 있는 [18F]트리플루오로메틸-L-
트립토판 ([18F]CF3-L-Trp)과 [18F]트리플루오로메틸-L-α-메틸트립토판 
([18F]CF3-L-AMT)을 설계하고 개발하려고 하였다. 또한 세로토닌 
영상화를 위한 표지된 트립토판 유도체의 가능성을 평가하기 위하여 
쥐의 뇌 내 분포와 대사를 조사하였다. 
 
방법:  
   [18F]CF3-L-Trp 또는 [18F]CF3-L-AMT의 전구체는 팔라듐 또는 수은 
촉매를 이용한 위치 선택적 요오드화를 통해 합성하였다. 
[18F]트리플로오로 메틸기는 methyl chlorodifluoroacetate와 
tetramethylethylenediamine를 넣고 구리 촉매 하에서 150C에서 15 분간 
반응하여 도입할 수 있었고, 이 후 보호기는 1 N 염산 수용액을 넣고 
100C에서 10 분간 반응하여 제거하였다. 반응 혼합물은 HPLC를 
이용하여 정제하였고, 분리된 [18F]CF3-L-Trp의 방사화학적 확인 및 순도와 
이성질체 확인 및 순도는 분석용 HPLC로 확인하였다. 생체 내 분포는 
정상 BALB/c 마우스에서 마취 없이 [18F]CF3-L-Trp를 주사한 후 10, 60 및 
120 분에 확인하였고, 자가방사기록은 SD 랫에서 주사 후 10 분째에 
확인하였다. PET 영상 역시 SD 랫에서 얻었으며, 마취 없이 [18F]CF3-L-
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Trp를 주사한 후 5, 10, 20, 40 및 80 분에 쥐를 희생시키고 뇌를 추출하여 
영상을 얻었다. 대사체 연구는 비방사성 CF3-L-Trp를 BALB/c 마우스에 
투여한 후 10 분 및 60 분째에 뇌, 혈액, 및 소변에서 샘플을 얻어 
HPLC와 LC/MS를 이용해 분석하였다. 세로토닌 대사가 증진된 SD 
랫에서 [18F]CF3-L-AMT의 뇌 분포 및 대사를 평가하기 위해 염화 리튬을 
하루 2 회 5일간 85 mg/kg을 복강주사로 SD 랫에 투여하였다. 
 
결과:  
   보호된 L-Trp및 브롬화와 요오드화 유도체를 이용해 
[18F]트리플루오로메틸화 반응을 수행하였고, 요오드화 유도체가 가장 
높을 표지 효율을 보였다. 표지 후, 산에 불안정한 보호기를 1 N 염산 
수용액을 사용하여 동시에 제거하였고, 반응 혼합물은 HPLC로 
정제하였다. 방사 화학적 수율을 분리된 생성물을 기준으로 
6±1.5%였으며, 방사 화학적 순도는 99% 이상이었고 [18F]CF3-L-Trp의 
머무름 시간은 합성한 표준물질과 동일하였다. 몰당 비방사능은 [18F]CF3-
L-Trp가 0.44–0.76 GBq/μmol이고 [18F]CF3-L-AMT가 0.94–1.46 GBq/μmol으로 
친핵성 치환반응으로 합성한 18F-표지된 화합물보다는 비교적 낮지만 
생체 내 적용을 하기에는 충분하였다. 거울상 이성질체 확인 및 순도는 
키랄 HPLC에 의해 측정되었고 다른 이성질체는 발견되지 않았다. 10 
분에 생체 분포에서 [18F]CF3-L-AMT와 [18F]CF3-L-Trp의 뇌 섭취량은 각각 
2.27 ± 0.14%ID/g와 2.06 ± 0.22%ID/g 이었고 [18F]CF3-L-AMT의 뇌 섭취 
(0.73 ± 0.08%ID/g)는 [18F]CF3-L-Trp (0.43 ± 0.08%ID/g)보다 60 분에서 
유의하게 높았다. 이 결과는 α-메틸화가 MAO에 의한 대사를 
감소시킴으로써 두뇌의 보유를 증가 시킨다는 것을 나타냈다. 60 분 
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(4.50 ± 0.47%ID/g)에서 [18F]CF3-L-AMT의 골 흡수는 [18F]CF3-L-Trp (9.34 
± 0.62%ID/g)의 골 흡수보다 현저히 낮았으며 두 화합물 모두 신장에서 
높은 섭취를 보였다. PET 및 자가방사기록에서, 솔기핵 (지느러미 및 
내측)의 섭취는 비교적 매우 낮았다. 대신 송과선, 시상, 시상 하부 및 
중뇌는 특히 높은 섭취량을 보였다. [18F]CF3-L-Trp는 L형 아미노산 
수송체를 통해 혈뇌장벽을 투과하였고 [18F]CF3-D-Trp는 투과하지 
못하였다. 대사체 연구에서는 60 분에 뇌와 혈액에서 CF3-serotonin의 
피크가 검출되었고, LC-MS를 통해 CF3-serotonin의 질량 값을 
확인함으로써 뇌 및 혈액 내에서 CF3-L-Trp이 CF3-serotonin로 대사되는 
것을 증명하였다. 리튬 처리 한 SD 래트 뇌에서의 [18F]CF3-L-AMT의 
분포 패턴은 정상 SD 랫 뇌와 유사하였다. 그러나 리튬 처리한 SD 
래트에서 [18F]CF3-L-AMT 의 뇌 흡수율은 정상 SD 랫보다 약 10 분 더 
빨리 최고 농도에 도달하였고, 리튬 처리된 SD 랫트에서의 뇌 섭취는 
정상 SD 랫보다 더 오래 지속되었다. 
 
결론:  
   본 연구에서, 구리를 촉매로 한 [18F]트리플루오로메틸화를 이용해 
성공적으로 [18F]CF3-L-Trp를 합성할 수 있었고 2 번 위치의 
18F은 이 
물질이 세로토닌 대사에 특이적으로 작용할 수 있도록 하였다. 하지만 
뇌에서의 빠른 배출과 높은 생체 내 탈 불소화는 [18F]CF3-L-Trp가 
세로토닌을 영상화하는데 적합하지 않음을 보여 주었다. 트립토판의 α-
메틸화는 대사를 줄임으로써 뇌의 머무름 시간을 증가시켰으며 생체 내 
탈 불소화를 감소시켰다. 하지만 낮은 솔기핵 섭취는 [18F]CF3-L-AMT의 
PET 영상이 세로토닌 대사를 반영하는 지를 불분명하게 하였다. 또한 
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뇌에서의 [18F]CF3-L-AMT가 대사되지 않은 채 남아있음으로써 대사된 
것과 대사되지 않을 것을 구분하기 어렵게 하여 절대적인 세로토닌 합성 
속도 얻는 것을 어렵게 하였다. 그럼에도 불구하고 실험 결과들은 정상 
및 리튬 처리된 SD 랫에서 [18F]CF3-L-AMT의 분포 패턴이 세로토닌 작용 
및 대사와 관련이 있음을 시사하였다. 따라서 [18F]CF3-L-AMT는 세로토닌 
대사를 영상화할 수 있는 PET 영상제로 사용될 가능성이 있으나 더 많은 
검증이 필요하다.  
주요어: [18F]트리플루오로메틸화; CF3-L-Trp; 세로토닌; 5-HT; 트립토판; 
아미노산; 모노 아민 산화 효소; α-메틸트립토판. 
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